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ABSTRACT 
 
NOVEL REGULATORY MECHANISMS BY WHICH LARGE T ANTIGEN 
COORDINATES THE MERKEL CELL POLYOMAVIRUS LIFE CYCLE 
Jason Diaz 
Dr. Jianxin You 
 Due to its association with Merkel cell carcinoma (MCC), a substantial effort has 
been made to better understand how Merkel cell polyomavirus (MCPyV) proteins drive 
oncogenesis; however, our understanding of the early steps of MCPyV infection remains 
poor.  The polyomavirus Large Tumor antigen (LT) is a highly multi-functional protein 
with a wide range of activities, including: stimulation of cellular proliferation through its 
interaction with retinoblastoma protein and DnaJ heatshock protein family members; 
arrest of the cell cycle through a poorly understood activity localized to the C-terminal 
region; and regulation of the initiation of viral DNA replication.  LT proteins also play 
important roles in regulating viral transcription.  How these various functions are 
regulated to ensure an orderly progression of events conducive for the viral life cycle has 
not been well established.   
 In this study, I show how phosphorylation of MCPyV LT plays an important role 
in regulating its many functions.  I identify threonines 297 and 299 as key phospho-sites 
which regulate LT’s ability to initiate replication.  T297 phosphorylation inhibits LT 
binding to the viral origin of replication and acts as an “off” switch, while 
phosphorylation of T299 is required to stimulate LT-mediated replication of viral 
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genomes.  This study was the first to identify phosphorylation sites of LT and link them 
to important protein functions.   
 Cross-reactivity to a phospho-specific antibody revealed yet another 
phosphorylation site on MCPyV LT as S816.  We discovered that this phosphorylation 
event is mediated by ATM kinase, and may play a role in the MCPyV LT C-terminal 
domain’s ability to arrest the cell cycle.  This study helps to further elucidate MCPyV’s 
association with the host DNA Damage Response (DDR) and provides some rational for 
the recruitment of these factors to viral replication centers.   
 Finally, studies of the viral non-coding control region (NCCR) reveal a surprising 
interaction between LT and sT on the late promoter.  MCPyV LT is able to robustly 
stimulate the late promoter only in the context of an intact Ori and sT co-expression.  
Using phosphomutant LTs and mutant Ori sequences, I highlight the importance of LT 
binding to the Ori and stimulation of replication as key factors in LT-mediated activation 
of the late promoter in the context of sT co-expression.  LT alone actually represses the 
late promoter and requires sT coexpression to efficiently stimulate the late promoter after 
replication.  This study therefore reveals an important dependence on sT expression for 
the regulation of transcription that has not yet been reported with other polyomaviruses.  
 In sum, this study demonstrates multiple mechanisms of regulation including 
protein phosphorylation, protein-DNA interactions, and co-expression of key viral 
proteins as regulators of LT function.  These studies may help elucidate critical factors 
required for establishing a robust cellular infection system which is greatly needed to 
further our understanding of the basic virology of this important human tumor virus.             
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CHAPTER 1: INTRODUCTION 
 
1.1: Merkel Cell Carcinoma and Merkel Cell Polyomavirus 
1.1.1 Merkel Cell Carcinoma 
 Merkel cell carcinoma (MCC) was first described in 1971 by Cyril Toker as a 
trabecular tumor of the dermis (1). MCC is thought to arise from Merkel cells, a unique 
cell type of the skin, which transmit fine-touch sensation and have characteristics of both 
epithelial and neurosecretory cells (2).  MCC was long regarded to be a rare cancer, with 
an incidence of around 2 cases per million in 1984, but this rate has tripled over 
subsequent decades. Old age, immune suppression, and UV exposure are the major risk 
factors for MCC disease (3,4). Although rare, MCC is a very aggressive cancer, with a 
mortality rate as high as 30% (5). 
 
 Risk of MCC increases dramatically at older ages, and is also increased with 
immunosuppression (4).  These factors led Chang and Moore to investigate whether 
MCC was associated with an infectious agent.  Using Digital Transcriptome Subtraction, 
they identified a unique transcript expressed at extremely high levels in these tumors, 
which did not match known human transcripts; sequence analysis showed that it was 
homologous to the major viral protein of polyomaviruses, the Large Tumor (LT) antigen.  
Using PCR and sequencing techniques, they were then able to identify a novel 
polyomavirus clonally integrated within the genomes of the four tumor samples they 
analyzed.  They named this new polyomavirus Merkel cell Polyomavirus (MCPyV) for 
its association with MCC (6).  Subsequent analysis of MCC tumors have shown that 
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MCPyV sequences can be found in at least 80% of all MCC cases examined, although 
more recent advances in detection methods has shown an association as high as 97% (7).  
MCPyV is the first human polyomavirus that has been associated with a human cancer 
and has generated a lot of interest in the tumor virology field.   
   
1.1.2 Merkel Cell Polyomavirus and Cancer 
 Polyomavirus associated cancers are generally driven by the expression of LT (8).  
The N-terminal half of LT can bind to many cellular proteins, including DnaJ family 
members and pRb, to drive host cell proliferation.  The C-terminal half of LT is 
important for initiating replication from the viral origin, and includes an origin binding 
domain (OBD) and a helicase domain.  Interestingly, LT was found to be expressed in a 
truncated form in almost every MCPyV-associated MCC tumor analyzed (9).  While the 
truncations were unique to every tumor, they universally deleted the C-terminal half of 
the protein required for viral replication while retaining the N-terminal half, which could 
still inhibit key tumor suppressors like pRb.  This led Chang and Moore to initially 
hypothesize that viral replication of the integrated MCPyV genome was antithetical to 
tumor progression, a theme shared with papillomavirus associated cancers.  In support of 
this hypothesis, they described a unique MCC tumor that retained wild-type expression of 
LT, but had a mutated origin of replication (Ori350), rendering the integrated sequence 
replication incompetent (9,10).  These observations bear a striking resemblance to 
papillomavirus associated cancers, where deletion of the major regulatory protein E2 
decreases replication from the viral origin and induces overexpression of the viral 
oncogenes (11,12).  Since that initial hypothesis, further study of the C-terminal domain 
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has also revealed a growth-inhibitory property linked to the activation of a host cell DNA 
Damage Response (DDR), and it has been hypothesized that this region of LT is 
therefore negatively selected during oncogenesis (13,14).  
 
 Since its discovery in 2008, many reagents and tools have been developed to 
study MCPyV prevalence.  Generation of a monoclonal antibody against MCPyV LT 
allowed investigators to screen MCC tumors for presence of the viral antigen, while 
production of viral particles allowed studies of viral infection to be performed in cell 
culture and provided a capture method for screening human sera for antibodies against 
MCPyV (15-20).  Serological studies indicate that MCPyV seroconversion occurs early 
in childhood and that most adult individuals harbor antibodies against MCPyV 
(16,18,19).  In agreement with this finding, Rolling Circle Amplification and deep 
sequencing of DNA obtained from skin tissue gave evidence of chronic shedding of 
MCPyV in healthy human donors (21,22).  These observations suggest that MCPyV 
establishes an early, persistent, subclinical infection, and that a rare few individuals go on 
to develop MCPyV related cancer. 
 
 Given its early and ubiquitous infection in human skin, it is vital to understand 
basic MCPyV virology and how viral infection leads to cancer.  Extensive study of the 
prototypical polyomavirus, Simian Virus 40 (SV40) has given the field a strong 
foundation for understanding MCPyV associated oncogenesis, but this framework has 
only taken us so far.  Many key differences unique to MCPyV have already been 
described.  Phylogenetically, MCPyV is more closely grouped with murine polyoma 
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virus instead of SV40; this is in contrast to the better described human polyomaviruses 
JK and BC virus (6,8,23).  Additionally, MCPyV LT bears two important differences 
from its SV40 counterpart.  The first is the existence of an N-terminal 200 amino acid 
stretch of peptide flanking the pRb binding site not found in any other polyomavirus LT; 
this region has been termed the MCPyV Unique Region (MUR) (24,25).  The second 
major difference is that MCPyV LT does not appear to bind the key tumor suppressor 
p53 (or binds with extremely low affinity), a finding that challenges conventional 
understanding of polyomavirus-associated oncogenesis (26).  MCPyV sT also appears to 
act differently than its SV40 homologue: MCPyV sT plays a much more dominant role in 
tumorigenesis, and interacts with its key cellular target, PP2A phosphatases, in ways 
distinct from SV40 sT (27).  Finally, the non-coding control region (NCCR) of the viral 
genome, which bisects the circular genome into an early and late region, is organized 
more similarly to mouse polyomavirus genome architecture than the more extensively 
studied SV40 NCCR (10,28).  Regulation of both gene expression and replication 
through the NCCR may be different for MCPyV than SV40; indeed, recruitment and 
assembly of the origin binding domains of MCPyV LT around the viral origin has already 
been shown to be unique (28).  The focus of my work has been to further our 
understanding of how MCPyV LT’s multiple functions are regulated through post-
translational modifications.  I have also sought to better elucidate how viral transcription 
from both the early and late promoters is regulated, which will both shed new light on 
MCPyV persistent infection and might also explain how expression of viral oncogenes 
during tumorigenesis is regulated. 
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1.2 Merkel Cell Polyomavirus Virology 
1.2.1 MCPyV Genes and Genome Organization 
  
 
 
 
  
 
Figure 1.1  Organization of the MCPyV genome.  The genome is bisected into two regions by a central 
non-coding control region (NCCR) which contains the promoters for the early and late genes, as well as 
the viral Origin of Replication (Ori).  The Tumor Antigen is expressed early in infection, and is multiply 
spliced into many proteins, including Large T antigen (LT), small T antigen (sT), antigen of 57 kDa 
(57kT), and Alternate frame of the Large T Open reading frame (ALTO).  The capsid proteins VP1 and 
VP2 are expressed following genome replication.        
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 MCPyV is a double-stranded DNA virus with a circular genome of about 5.3kb 
protected by an icosohedral capsid.  The genome is divided into two regions by an NCCR 
housing the origin of replication (Ori) and promoter sequences (Figure 1.1).  The early 
and late regions flank this NCCR in opposite directions.  The Tumor-antigen open 
reading frame is expressed from the early promoter and multiply spliced into mRNAs 
expressing four products: Large T antigen (LT), small T antigen (sT), 57kDa T antigen 
(57kT), and Alternate frame of the Large T Open reading frame (ALTO).  These 
nonstructural genes primarily manipulate the host cell and are also responsible for 
replication of the viral genome.  From the late promoter, two capsid proteins (VP1 and 
VP2) are expressed which package viral genomes into nascent virions. Of these viral 
proteins, both MCPyV LT and sT proteins have been found expressed in MCPyV related 
tumors and have therefore been the most extensively studied thus far (6,8,23). 
 
1.2.2  Large T Antigen 
 Like other polyomavirus LT proteins, MCPyV LT can bind pRb and DnaJ family 
members, which drives host cell proliferation; the domains responsible for these 
functions generally remain intact in virus-associated MCC as well, and are likely a 
driving force for proliferation of these tumors (9).  Classically, polyomavirus LTs bind 
and inhibit the tumor suppressor p53; the dual inhibition of pRb and p53 is a common 
feature of oncogenic DNA viruses like papillomaviruses and certain herpesviruses (29). 
Association of p53 with MCPyV LT has only recently been reported, but this interaction 
was weak and concluded to be indirect (26); additionally, the p53 binding domains of 
SV40 LT lie within the helicase domain, which in most MCPyV associated tumors is 
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deleted from LT due to nonsense mutations in the LT gene (9).  MCPyV may be unique 
among polyomaviruses for lacking a direct interaction with p53; in fact, LT expression 
may actually activate p53 downstream signaling indirectly through activation of the host 
DDR (14).  Further investigation is required to better understand MCPyV’s relationship 
with this key tumor suppressor.   
 
 MCPyV LT encodes a 200 amino acid stretch flanking the LXCXE pRb binding 
motif which is not found in any other polyomavirus LT.  The function of this MUR 
remains largely unknown.  A host protein involved in the fusion of lysosomes, Vam6p, 
was identified as a LT binding partner in cells which associated with the MUR, but the 
functional relevance of this interaction in relation to the viral life cycle has not been 
elucidated (24). Finally, like other polyomaviruses, MCPyV LT is necessary and 
sufficient for the initiation of replication from the viral Ori in the NCCR (10), which will 
be reviewed in depth below (1.3) and will be the focus of the work presented in Chapter 
2.      
  
 In SV40, LT is necessary and sufficient for transforming cells in culture, while sT 
plays a lesser role in transformation (30,31).  In contrast, expression of MCPyV LT alone 
is not sufficient to transform any cells studied thus far.  In fact, expression of wild type 
LT commonly leads to growth arrest, a feature that has been localized to an activity 
intrinsic to the C-terminal domain, which is commonly deleted in MCPyV associated 
tumors (13,14).  This growth arresting activity requires wild type p53 activity and a host 
DNA damage response instigated by the C-terminal portion of LT, and likely explains 
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why MCPyV LT has poor transformation activity when expressed alone (14). Truncated 
LT’s with this inhibitory activity deleted may still play an important role in 
tumorigenesis, however, as mouse xenograph transplant experiments have demonstrated 
a requirement for tumor-derived LT in MCPyV associated MCC tumors (32).    
 
1.2.3  MCPyV Small T Antigen 
 MCPyV sT has emerged as a key player in MCPyV associated oncogenesis.  
Early studies of sT confirmed that its expression can transform rat cells, and it is 
commonly expressed in many MCPyV associated tumors (27,33,34).  Like other 
polyomaviruses, MCPyV sT shares its N-terminal DnaJ domain with LT, while its C-
terminal half encodes a PP2A phosphatase binding domain.  SV40 sT’s contribution to 
oncogenesis has been linked to its ability to bind and inhibit PP2A phosphatases, thereby 
preventing the dephosphorylation of Akt, rendering it constitutively active (35-37).  
MCPyV sT, in contrast, acts further downstream of Akt, and is able to induce 
hyperphosphorylation of 4E-BP1, thereby releasing eIF4E to stimulate cap-dependent 
translation, independently of PP2A binding (27).  The PP2A binding domain of MCPyV 
sT is not dispensable, however; this domain allows it to bind the adaptor protein NEMO, 
possibly in complex with certain PP2A or PP4A subunits, to disrupt host cell 
inflammatory signaling mediated by NF-κB (38).  Additionally, PP2A binding by 
MCPyV sT was shown to destabilize microtubules by disregulating phosphorylation of 
stathmin, a key microtubule binding protein (39).  This destabilization led to increased 
cell migration and invasion, and may explain why MCC tumors are prone to rapid 
metastases (39).   
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 MCPyV sT has also been shown to stabilize the expression of MCPyV LT 
through its inhibition of the E3 ubiquitin ligase SCFFbw7 (40).  This stabilization of LT is 
unique to MCPyV, as other sT proteins generally don’t affect the protein levels of their 
cognate LT proteins.  LT-mediated replication of viral origins is greatly enhanced when 
sT is also expressed, once again highlighting sT’s more prominent role in MCPyV 
(10,40).   
 
1.2.4 Additional Early Gene Products 
 The other two viral proteins, 57kT and ALTO, are much less understood.  57kT is 
an alternatively spliced T-antigen of 432 amino acids (9,41).  It shares the first 332 amino 
acids of LT, including the DnaJ and pRb binding sites, the MUR and a nuclear 
localization signal, but lacks LT’s origin binding domain and the majority of the helicase 
domain.  It similarly shares its C-terminal 100 amino acids with LT.  Robust expression 
of 57kT appears to require viral replication but its function remains unknown.  It is 
sometimes compared to SV40’s 17kT, a small protein which similarly shares sequences 
with its cognate LT, and which appears to behave both independently and in concert with 
other T-antigens to control cellular proliferation (42,43).  Given that 57kT retains both 
tumor suppressor (DnaJ, pRb) binding domains and the C-terminal region of LT shown to 
inhibit growth, it will be interesting to study this protein’s role in cell cycle manipulation 
and investigate what role(s) it plays during natural infection.   
  
 The overprinting gene, ALTO was discovered as a cryptic reading frame within 
the T-antigen locus that is evolutionarily related to the murine polyomavirus middle T 
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antigen (44).  Its expression can be detected in cells carrying MCPyV molecular clones 
but its role during infection remains to be elucidated (44).   
 
1.2.5  MCPyV Late Genes 
 The late region of MCPyV encodes two capsid proteins, VP1 and VP2.  A third 
capsid gene, VP3, is predicted by sequence analysis but has never been shown to be 
expressed; indeed, attempts to express this capsid have failed (17).  These proteins are 
expressed after replication and encapsidate newly replicated viral genomes into nascent 
virions.  The major capsid protein, VP1, is necessary and sufficient for the production of 
psuedovirions.  VP2 is a minor capsid protein which is required for efficient infection of 
a number of cell lines, although its precise mechanism of action remains to be fully 
explored (19,41,45,46).  Initial reports identified sialic acid as the major attachment 
factor for MCPyV, similar to other polyomaviruses (47).  Subsequent studies have 
uncovered a more nuanced process where binding to sulfated glycosaminoglycans, 
especially heparin sulfate, was required in addition to sialic acid for efficient entry (46).  
The crystal structure of VP1 confirmed a sialic acid binding pocket, but mutation of this 
domain did not inhibit initial attachment of virions to target cells, supporting a model 
where heparin sulfate acts as an initial attachment factor with subsequent binding of sialic 
acid required for internalization into the target cell (48).  This dual-receptor paradigm is 
novel among polyomaviruses, once again highlighting MCPyV’s novelty. 
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1.2.6 Natural Infection of MCPyV 
 Thus far the natural host cell of MCPyV has not yet been identified.  Merkel cells 
are post-mitotic and do not support robust infection of MCPyV, and are thought to be a 
dead-end host cell.  The lack of a robust in vitro system for propagating the virus has 
hampered our ability to thoroughly study MCPyV’s life cycle, so research efforts have 
thus far studied various aspects of the virus life cycle in isolation.  For example, 
psuedovirions composed of the viral capsids encapsidating either an MCPyV molecular 
clone or a reporter construct have been useful in better understanding viral entry (46-48).  
Similarly, ectopic expression of viral proteins alone or in combination allowed for the 
discovery of many of the functions described for LT and sT in sections 1.2.2 and 1.2.3 
above.  Additionally, identification of cell lines that support replication of the viral Ori 
have allowed for an in-depth exploration of this key step of the viral life cycle 
(10,17,41,49,50).   
  
 To date, a significant portion of MCPyV research has focused on the oncogenic 
properties of both LT and sT.  Regulation of key processes such as genome replication 
and transcription remains to be thoroughly explored.  A better understanding of how 
these early events are regulated during natural infection can provide clues for 
understanding how these processes might then be altered during oncogenesis, and may 
even point to therapeutic targets in MCPyV associated tumors.    
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1.3 Polyomavirus Genome Replication 
1.3.1  LT-mediated Initiation of Replication 
 SV40 replication has been an essential model for understanding eukaryotic 
replication (51).  This section will review the formation of the polyomavirus replication 
initiation complex, directed by LT, followed by mechanisms of regulation in section 
1.3.2.  A discussion of our current understanding of MCPyV replication will be the focus 
of section 1.3.3.  
 
  
  
 
 The SV40 Ori is located at the center of the NCCR, and is flanked on both ends 
by the early and late promoters.  The Ori is comprised of three functional domains (see 
Figure 1.2, bottom).  The central domain, Site II, contains four GAGGC pentanucleotide 
repeats which serve as LT binding sites.  Site II is flanked on the early side by the Early 
Palindrome (EP) and on the late side by an A/T rich tract (A/T), both of which are easily 
Figure 1.2  Organization of polyomavirus origins of replication.  Pentanucleotide sequences (GAGGC) 
which are recognized by LT are denoted with a “P” and highlighted in blue, while inverted complimentary 
binding sites (CTCCG) are highlighted in magenta.  Arrows denote the orientation of bound LT.  The A/T 
rich tract (A/T) and Early Palindrome (EP) are also indicated. Py – murine polyomavirus. Adapted from 
Harrison et al., 2011 (28).     
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melted and serve as the initial sites of unwinding and recruitment of the DNA replication 
machinery (51).  
 
 SV40 LT binds the viral origin and forms hexameric complexes to initiate 
replication.  LT contains two domains critical for replication: an OBD and a helicase 
domain.  The OBD specifically recognizes the GAGGC pentanucleotide repeats of Site 
II, and additionally make contacts with the other OBD of adjacent LT molecules during 
hexamer formation (52,53).  The helicase domain makes non-specific interactions with 
DNA, especially single stranded DNA, and helps stabilize LT recruitment to the Ori.  The 
helicase domain also contains an ATPase domain required for unwinding activity; this 
activity can be stimulated by single stranded DNA (54-56).  In addition to forming a viral 
helicase required for unwinding of the genome, LT recruits key cellular replication 
factors including RPA70, RFC1 and DNA Polymerases to the viral origin (51,57).    
 
 LT is the only viral protein required for initiating replication of the genome.  
Biochemical analysis of a variety of LT mutants, as well as extensive structural analyses, 
have allowed for a deep understanding of the initial events of replication initiation, which 
will be briefly summarized. The OBD recruits LT specifically to the viral Ori, where the 
arrangement of the GAGGC pentanucleotides causes a head-to-head configuration of LT 
molecules (53).  These LT proteins then recruit additional LT molecules to form two 
hexameric complexes at the Ori (58).  During hexamer formation, the OBDs release the 
Ori DNA and form contacts with each other to stabilize the hexamer, while the non-
specific DNA interactions from the helicase domains keep the complexes localized to the 
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viral genome (53).  The ATPase activity of the helicase domains are then activated and 
the hexameric complexes begin unwinding the viral genome at the A/T and EP domains 
flanking Site II.  After initial unwinding of the DNA, the LT helicase continues to 
unwind the genome as the cellular replication machinery, recruited by LT, begins 
replicating the viral genome.  In vitro replication studies have shown that magnesium and 
ATP are required to stimulate helicase activity, while initial hexamer formation of LT 
requires ATP binding but not hydrolysis, as non-hydrolizable analogues can still 
stimulate hexamer formation (53,58-70).      
  
1.3.2 Regulation of Viral Replication 
 In addition to orchestrating replication of the viral genome, LT has many other 
important functions which are required for manipulating the host cell to drive 
proliferation, as has been outlined above.  Initiation of replication must be timed to occur 
when the host cell is most permissive to replication.  This switch is mediated by 
phosphorylation of LT at threonine 124 (T124) (71,72).  Phosphorylation at T124 is 
required for LT to be replication competent, and is thought to stimulate interactions 
between both hexamers at the Ori which lead to initiation of unwinding (73).  Cyclin 
dependent kinases have been shown to phosphorylate LT at this site in vitro, but have not 
been definitively proven to perform this function in vivo (71).  In addition to T124, 
phosphorylation at serines 120 and 123 plays an indirect role in regulating replication.  
Specifically, S120/123 phosphorylation is required for efficient nuclear import of LT but 
diminishes LT’s ability to initiate replication.  These phosphorylation marks must be 
removed prior to replication, likely by PP2A phosphatases.  The kinase(s) responsible for 
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phosphorylating S120/123 remains to be confirmed, but these phosphorylation events can 
be simulated in vitro with casein kinase (74-79).   
 
 Many DNA viruses have been shown to manipulate the host DDR for their 
replication.  SV40 has been shown to recruit DDR factors to viral replication foci (80).  
Additionally, ATM kinase, a key regulator of double-strand break repair, has been shown 
to phosphorylate LT directly, and this activity was required for replication (81).  While 
the interaction between SV40 and the host DDR has been well documented, the 
functional/mechanistic role(s) of these DDR proteins still requires exploration.      
 
1.3.3  MCPyV Genome Replication  
 MCPyV genome replication follows the SV40 model to a large extent.  MCPyV 
LT is the only protein required for initiating replication, although co-expression of sT can 
boost LT’s activity by stabilizing LT protein expression (10).  MCPyV LT recognizes the 
viral Ori through its OBD; neither SV40 nor MCPyV LT can recognize the other’s Ori at 
a level that allows for replication (28).  Interestingly, the MCPyV Ori is organized more 
similarly to the murine polyomavirus Ori (Figure 1.2, top): it lacks a true early 
palindrome region and instead has two A/T tracts that flank the central pentanucleotides. 
Additionally, instead of having a symmetrical set of four GAGGC pentanucleotides at the 
center of the Ori, MCPyV contains ten GAGGC repeats within the NCCR, eight of which 
are relevant to replication; LT binds four of these repeats in an asymmetric fashion (P1, 
P2, P4 and P7) which has been shown to be similar to murine polyomavirus LT’s origin 
binding architecture (10,28,82).  Notably, crystal structures predict that MCPyV LT 
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OBDs make more extensive contacts with each other on the viral origin compared to 
SV40 LT (28).  Novel to MCPyV replication is LT’s ability to recruit the host protein 
Brd4 to replication foci, which in turn recruits Replication Factor C; this activity was not 
seen with SV40 LT, but has been shown to be relevant to papillomavirus replication 
(50,83).  Similar to SV40, however, is the recruitment of host DDR proteins to actively 
replicating MCPyV viral genomes (49).  The recruitment of these proteins appears to be 
necessary for efficient replication of the viral genomes in cells, although the detailed 
mechanisms by which these DDR proteins assist replication remain to be elucidated (49).  
Recruitment and manipulation of the host DDR has emerged as a common theme among 
DNA viruses, and MCPyV LT expression alone can elicit a robust DDR in cells, even in 
the absence of viral genomes (14).   
 
 Important questions remain for MCPyV replication.  The role(s) played by DDR 
proteins at replication foci remains to be elucidated.  Additionally, contribution from sT 
beyond its stabilization of LT has yet to be explored in the context of replication.  Finally, 
whether MCPyV LT is phosphorylated as a means of controlling the replication process 
has not yet been described.   
 
1.4 Regulation of Polyomavirus Transcription 
1.4.1 SV40 Gene Regulation 
 Regulation of both early and late promoters for SV40 has been well described.  
The early promoter contains binding sites for many cellular transcription factors, 
including Sp1, Sp2, AP-1, AP-4 and NFAT (84-87).  A TATA box targets the 
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transcription machinery to the correct start site (88).  As expression of LT increases 
during early infection, the early promoter becomes inactivated.  During and especially 
after LT has initiated replication of viral genomes, the early promoter is shut down while 
the late promoter is activated to express the capsid proteins (87).  LT directly mediates 
the repression of the early promoter and activation of the late promoter; sT’s involvement 
in either event has not been well established, although one report shows that sT can help 
compliment the activity of a sub-optimal level of LT expression (89).   
  
1.4.2  MCPyV Gene Regulation  
 Regulation of MCPyV transcription has thus far not been studied.  Only a few cell 
lines support expression of viral proteins from their natural promoters, and the few 
reports on the topic are largely observational.  Expression of viral proteins from native 
MCPyV genomes is highly restricted in all cell lines tested thus far (14,41,45,46,49,90); 
the mechanism(s) regulating viral MCPyV transcription remains unexplored.  A better 
understanding of how the viral promoters, especially the early promoter, are regulated is 
vital for understanding viral oncogene expression in MCPyV associated cancers as well 
as in naturally infected cells.   
 
1.5 Scope of My Work 
 My work has focused on early events of MCPyV infection, including replication 
and transcription, and has also explored how post-translational modifications regulate LT 
function.  In Chapter 2, I identify three novel phosphorylation sites on MCPyV LT and 
go on to describe how they regulate LT-mediated replication of viral genomes.  In 
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Chapter 3, I identify a fourth phosphorylation site on the extreme C-terminus of LT and 
demonstrate how this phosphorylation event, mediated by ATM kinase, may contribute to 
the growth-inhibitory properties of the C-terminal region of LT.  Finally, in Chapter 4 I 
offer a preliminary analysis of MCPyV transcription from both early and late promoters.  
I describe how replication is tied to transcriptional activation and demonstrate a unique 
dependence of LT on sT co-expression for upregulation of the viral late promoter.       
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CHAPTER 2: PHOSPHORYLATION OF LARGE T ANTIGEN REGULATES 
MERKEL CELL POLYOMAVIRUS REPLICATION	  
 
 I was the principal investigator who designed and performed the experiments in 
this chapter, and prepared the associated manuscript published in Cancers.  Jing Jiao 
prepared the LT sample for mass spectrometry analysis, which was performed by the 
School of Medicine Proteomics Core (Figure 2.1A), while I performed the protein 
alignment (Figure 2.1B).  Dr. Jianxin You assisted in modeling the extended OBD of LT 
in contact with DNA (Figure 2.2).  Sabrina Tsang assisted in performing the replication 
assay in Figure 2.5.  Dr. Xin Wang was of great assistance in performing the in vitro 
biochemical assays to probe the LT phosphomutants for their ability to bind and unwind 
the viral origin (EMSA in Figure 2.6, Unwinding Assay and Helicase assays in Figure 2.7 
and 2.8).   
 
 
 
 
 
 
 
This research was originally published in Cancers.  Jason Diaz, Xin Wang, Sabrina H. 
Tsang, Jing Jiao, and Jianxin You.  Phosphorylation of Large T Antigen Regulates 
Merkel Cell Polyomavirus Replication.  Cancers (2014) 6(3): 1468-86 
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2.1: CHAPTER SUMMARY 
 Polyomavirus Large T antigen (LT) is a multifunctional protein which 
manipulates the host cell and regulates replication of the viral genome as well as 
transcription of both the early and late promoters.  These multiple functions must be 
closely regulated to ensure each step of the viral life cycle is executed correctly.  
Phosphorylation is a major regulator of protein function, but no studies have yet been 
performed for MCPyV LT.  Using mass spectrometry, I identified three phosphorylation 
sites in MCPyV LT: T271, T297 and T299.  T299 is homologous to a highly conserved 
threonine found in all the major polyomavirus LTs I examined; phosphorylation of the 
homologous threonine in SV40 LT stimulates its ability to initiate viral replication. Using 
the tools already developed in our lab for studying MCPyV replication, I showed by 
immunoflourescene and southern blotting that alanine mutants of MCPyV LT T297 and 
T299 dramatically affected viral replication without affecting recruitment of replication 
factors: T297A stimulated replication well over levels seen by wild-type LT, while 
T299A was replication defective, as was predicted by homology to SV40 LT.  Further 
biochemical analyses showed that th MCPyV LT T297A mutant could bind the origin of 
replication with increased affinity, while the T299A mutant had reduced binding, 
compared to wild-type.  The unwinding and helicase activities of LT was unaffected by 
these mutations.  These results showed that phosphorylation at two sites in MCPyV LT 
dramatically regulates its ability to replicate, and identified a third, novel site at T271 in a 
unique region of MCPyV LT that warrants further investigation.   
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2.2: INTRODUCTION 
 MCPyV is the first human polyomavirus to be linked to a human cancer MCC 
(3,6,8).  Since its discovery in 2008, this virus has been found clonally integrated in a 
majority of MCC tumors. In most MCPyV related MCC tumors the major viral protein, 
LT, has been mutated such that it is expressed in truncated forms (9).  These tumor-
derived truncated LT proteins retain their binding sites for pRb and DnaJ family 
heatshock proteins, thereby driving proliferation (3,9).  Indeed, at least one study has 
shown that tumors with knocked-down LT protein regress rapidly in a xenograft model 
(32). Both LT and the splice variant sT have been shown to have oncogenic properties 
(10,32,33,91), although the precise contribution of each protein to the process of 
tumorigenesis is still unclear.     
 
 MCPyV appears to be a natural resident of the skin microflora, and is acquired 
early in life (19,21,22).  While considerable efforts have been made to better understand 
MCPyV’s oncogenic potential, especially in MCC tumors, comparatively little work has 
been done to better understand this virus’s basic life cycle.  The lack of a relevant cell 
culture system for propagating virus has made investigations of its basic virology 
difficult; however, ectopic expression of MCPyV LT in cell lines such as HEK 293, 
C33A and U2OS has been valuable in enhancing our understanding of MCPyV’s 
interaction with host cells (14,41,50,92). 
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 Our lab has previously characterized MCPyV LT’s interaction with the host cell 
to stimulate replication (50).  In that study we showed by immunoflourescent staining 
(IF), fluorescent in situ hybridization (FISH) and BrdU staining that MCPyV LT proteins 
form large nuclear foci which contain actively replicating plasmids carrying the viral Ori.  
We also showed that several cellular factors colocalize to these foci, including: the 
double bromodomain protein, Brd4, the PCNA loading protein replication factor 1 
(RFC1), and the single-stranded DNA binding protein RPA70. In another study we 
demonstrated that full length MCPyV LT activates host DNA damage response (DDR) 
pathways and dramatically alters the host cell cycle (14).  Additionally, members of the 
DDR pathway were seen to colocalize with nuclear foci containing actively replicating 
viral genomes, potentially contributing to viral replication (49).  While it is still unclear 
whether DDR activation and recruitment upon LT expression is a side-effect of active 
viral replication and/or LT helicase activity, or if this activation is being actively 
subverted and manipulated by MCPyV, the link between MCPyV LT expression and 
DDR activation is well established.  This DDR activity, coupled with LT’s ability to 
dramatically alter the host cell cycle, may provide enough low-level genomic instability 
to lead to integration of the MCPyV genome into the host cell genome, which appears to 
occur in the majority of MCPyV-related MCC tumors (7).   
 
 Merkel cells may not represent the natural host cell of MCPyV and may pre-
dispose MCPyV to randomly integrate its genome.  Indeed, the prototypical 
polyomavirus SV40 has a transforming phenotype in cell lines that are non-permissive 
for viral replication (30); Merkel cells may similarly represent a non-permissive host for 
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MCPyV.  A better understanding of how MCPyV replication is regulated would provide 
a clearer framework for understanding how infection may be altered in Merkel cells and 
lead to integration of the mutated viral genome. 
 
 SV40 LT has been a model for understanding eukaryotic replication for decades 
(51).  SV40 LT is recruited to the viral Ori through its OBD, which recognizes GAGGC 
pentanucleotide repeats arranged symmetrically within the Ori.  LT then oligomerizes 
into two hexameric protein complexes arranged in a head-to-head fashion.  The C-
terminal helicase domains make non-specific contacts with an extended palindrome and 
an A/T rich tract flanking the central pentanucleotide repeats; these become the initial 
sites of unwinding.  SV40 LT then acts as a helicase to unwind the viral genome and 
recruits cellular factors to begin replication (51,57).  
 
 Phosphorylation has been a well established mechanism by which SV40 LT 
replication is regulated (93).  T124 was identified as a critical residue for regulating 
SV40 LT-mediated viral replication; removal of this phosphorylation either 
biochemically or genetically abrogated replication (71,94-96).  Intensive biochemical 
studies demonstrated that this phosphorylation plays an important role in mediating 
interactions between both hexamers at the Ori.  Alanine mutants are defective in forming 
double-hexamer complexes and unwinding the viral origin (68,73).  
 
 Somewhat paradoxically, early biochemical analyses of purified SV40 LT seemed 
to indicate that phosphatase treatment could actually stimulate viral replication in vitro 
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(75,78).  It was later clarified that, in addition to phosphorylation at T124, there are serine 
phosphorylation modifications nearby which have an inhibitory effect on viral replication 
(74).  These phosphorylation events seem to accumulate throughout the course of 
infection (97).  These observations led to a model where T124 phosphorylation stimulates 
replication, while subsequent phosphorylation at neighboring serines dampen this effect, 
potentially altering LT’s activity on the viral genome to favor transcription of the capsid 
genes (93).   
 
 No such analysis of MCPyV LT phosphorylation has yet been reported.  We 
sought to provide an initial framework for understanding the regulation of MCPyV LT’s 
functions by performing a proteomic analysis to search for relevant phosphorylation sites.  
Our studies identify three phosphorylation marks on MCPyV LT; T271, T297 and T299.  
We found that T271 had no effect on replication, while T297 and T299 phosphorylation 
had antagonistic effects.  Both T297 and T299 altered the binding affinity of MCPyV for 
the viral Ori while leaving unwinding and helicase functions largely intact.  Taken 
together, our data reveal a dynamic interplay between multiple phosphorylation sites, 
which together regulate MCPyV LT’s ability to initiate replication at the viral Ori.    
 
2.3: RESULTS 
2.3.1: Mass Spectrometry Identifies T271, T297 and T299 as Phosphorylation Sites on 
MCPyV LT 
 Polyomavirus LT proteins perform a large variety of functions in infected cells to 
establish a replicative niche; these functions include manipulation of the host cell cycle 
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through its DnaJ domain and pRb binding domain, regulation of viral transcription, and 
initiation of viral genome replication by acting as the viral helicase (8,31,93).  
Phosphorylation of LT has been well established as a mechanism of regulating its 
function, especially as a replication initiator protein.   
 
 To date, no analysis of MCPyV LT phosphorylation has been performed.  To get 
a broad view of MCPyV LT phosphorylation, we performed a mass spectrometry 
analysis to identify potential LT phosphorylation sites.  MCPyV LT was first affinity 
tagged with two IgG binding domains from S. aureus Protein A and a Tobacco Etch 
Virus (TEV) Protease cleavage site.  This construct was then ectopically expressed in 
HEK 293 cells.  The protein was affinity purified on IgG-Sepharose beads, separated by 
SDS-PAGE and stained with Coommassie blue (Figure 2.1A).  The visible band 
corresponding to MCPyV LT was excised and analyzed by mass spectrometry.   
 
 Trypsin-digested peptides from LT were purified and analyzed by LC/MS/MS.  
The peptides covered 45% of MCPyV LT and identified two unique peptides with a shift 
of 80 daltons over the predicted size, indicating a potential phosphorylation modification 
at T271 and T299.  We repeated this analysis using a titanium oxide column to enrich for 
negatively charged peptides, such as those with phosphorylated residues.  The peptides 
from this purification covered 25% of MCPyV LT and identified potential 
phosphorylation at T271 and T297 (Table 2.1).   
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 To better understand how these phosphorylation modifications may regulate 
MCPyV LT function, we aligned the amino acid sequence of various representative 
polyomavirus LT proteins (Figure 2.1B).  T271 localized to the serine rich unique region 
of MCPyV LT spanning amino acids 95-290.  Of the polyomavirus LT proteins analyzed, 
only murine polyomavirus contains such a tract; however, it is not well conserved with 
MCPyV LT. Although the lack of homology prevented us from making functional 
predictions of T271 phosphorylation, it is interesting to note this threonine was identified 
by multiple peptides in both mass spectrometry purification schemes (Table 2.1), giving 
us high confidence that this site is phosphorylated when LT is expressed in cells.    
 
 Threonine 297 is not well conserved amongst polyomavirus LT proteins.  Its 
function was not readily apparent to us based on homology, although its close proximity 
to the OBD led us to predict that it might have some impact on viral replication.  
Modeling of the OBD (aas 308-433) using the structure published by Harrison and 
colleagues (Figure 2.2A) (28), and extending their structure to include this threonine 
supported this hypothesis; T297 appears to face the protein/DNA interface and might 
even make direct contacts with DNA (Figure 2.2B).  In contrast to the two threonines 
discussed above, T299 is a highly conserved site found in all polyomavirus LT proteins 
analyzed.  The homologous site in SV40 LT, T124, has been well established as a key 
regulator of LT mediated DNA replication.  Phosphorylation of this threonine in SV40 is 
thought to regulate double-hexamer interactions on the viral origin to stimulate 
unwinding and melting of the DNA.  Alanine substitutions of this site in SV40 LT 
completely abolish LT-mediated DNA replication.  Our modeling of the OBD showed 
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that this threonine does not directly face the protein/DNA binding interface and likely 
plays a role in protein-protein interactions between LT monomers and/or hexamers 
(Figure 2.2C).  The crystal structure of the MCPyV OBD was solved in complex with 
DNA; since this structure did not include the T299 residue, we cannot rule out the 
possibility that T299 may interact with DNA in steps prior to hexamer assembly on the 
origin. 
 
 The sequence analysis and modeling led us to believe that phosphorylation of at 
least a subset of the threonines identified would play a role in viral DNA replication.  Our 
lab has previously studied MCPyV LT-mediated replication in C33A cells, an HPV-
negative cervical cancer cell line; we therefore took advantage of this system to probe the 
potential roles of these threonines in viral DNA replication.   
2.3.2:  MCPyV LT Phosphorylation Affects the Formation of Viral Replication Centers 
 To begin elucidating the role(s) these phospho-sites might play in replication, we 
generated alanine point mutants at each threonine identified by the mass spectrometry 
analysis.  We then co-transfected these constructs with a plasmid containing the MCPyV 
Ori into C33A cells and stained these cells for LT and various replication factors, as has 
been described in our previous study (50).  We assessed these mutants for their ability to 
form viral replication centers, which appear as nuclear foci, in transfected nuclei by IF.  
We also assessed their ability to recruit factors known to co-localize with MCPyV 
replication foci, including Brd4, RFC1 and RPA70.   
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 As has been shown previously, wild-type (WT) LT formed punctate foci in nuclei 
when co-transfected with a construct containing the MCPyV Ori.  Our previous studies 
have confirmed that under these transfection conditions these foci contain the MCPyV 
Ori plasmid (as shown by FISH) and are actively replicating (assessed by incorporation 
of BrdU) (49).  Both the T271A and T297A mutants formed replication foci while 
T299A completely failed to assemble replication foci (Figure 2.3A-C).  The T271A and 
T297A mutant LT proteins formed replication foci at altered rates.  Compared to WT LT, 
which formed replication foci in about 15% of LT positive nuclei, the T271A mutant had 
a small decrease in the frequency of replication focus formation (about 10%) (Figure 
2.3D).  This difference, however, was not statistically significant in a one-way ANOVA 
test.  In contrast, the T297A mutant exhibited twice as many LT-positive nuclei with 
replication foci.  For constructs which formed replication foci, recruitment of cellular 
factors did not seem to be affected; WT, T271A and T297A LT proteins all recruited 
Brd4, RFC1 and RPA70 proteins at similar rates.  Colocalization with T299A, which did 
not form replication foci, was not evident (Figures 2.3 and 2.4).  As has been seen 
previously, replication foci came in a variety of sizes, and nuclear swelling was often 
evident, especially in cells expressing T297A LT, possibly to accommodate rapidly 
replicating plasmids. 
2.3.3:  MCPyV LT Phospho-mutant Proteins Have Altered Replication Capacities 
 Our IF studies indicated that at least a subset of the threonines identified in our 
proteomic analysis affect viral genome replication.  To more rigorously examine these 
mutants’ ability to replicate plasmids containing the viral Ori, we performed Southern 
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blotting experiments to detect replicated plasmids.  C33A cells were co-transfected with a 
MCPyV LT construct and a plasmid containing the viral Ori.  Two days after 
transfection, cells were harvested and divided into two fractions.  Whole genomic DNA 
extracts were prepared from one fraction while proteins were collected from the other 
fraction.  Whole genomic DNA was then digested with BamHI to linearize the plasmids.  
The DNA was then detected with 32P-labeled MCPyV Ori plasmid as a probe.  The LT 
expression construct is made from the same vector backbone as the MCPyV Ori plasmid, 
and is therefore detected as a second, higher molecular weight band in our Southern blot.  
Additionally, the vector control for MCPyV LT is almost identical in size to the MCPyV 
Ori plasmid, so these two plasmids co-migrate as one band in our blots (Figure 2.5A, 
bottom).  Whole genomic DNA was also digested with DpnI to reveal newly replicated 
DNA (Figure 2.5A, top).    
 
 The Southern blotting results complemented what was seen by IF (Figure 2.3 and 
2.4).  Compared to WT MCPyV LT, the T271A mutant replicated the MCPyV Ori 
plasmid almost as well.  In contrast, the T297A mutant, which had twice as many nuclei 
with replication foci as WT (Figure 2.3D), had a robust replication phenotype that was 
well over that seen for WT.  This was especially striking given that both the amount of 
MCPyV Ori input plasmid and the protein level of T297A LT was less than WT (Figure 
2.5).  Finally, the T299A mutant, which failed to form replication foci as seen by IF, was 
unable to replicate Ori plasmids at a level detectable by Southern blot (compare Figure 
2.5A, top panel, Vector and T299A lanes).  This agrees with what was seen in SV40, 
where the homologous mutant, T124A, failed to replicate viral genomes.   
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2.3.4: T297A and T299A Phospho-mutant LT Proteins Bind the Viral Ori with Altered 
Affinity 
 Our studies up to this point confirmed that the T297A and T299A mutants had 
greatly altered replication phenotypes; T271A by contrast showed a modest effect on 
replication.  To get a firmer understanding of the molecular basis for the replication 
phenotypes we observed, we next sought to examine the binding, unwinding and helicase 
activities of these mutants.  We focused our analyses on the T297A and T299A mutants, 
which had dramatic replication phenotypes.   
 
 Polyomavirus LT binding of the viral Ori is mediated by its OBD, which 
recognizes GAGGC pentanucleotide repeats in the Ori.  The MCPyV Ori more closely 
resembles that of murine polyomavirus; it contains eight perfect GAGGC 
pentanucleotides and two imperfect pentanucleotides, with two A/T rich regions 
interspersed between these repeats (Figure 2.6A) (10,28,82).  Previous studies have 
shown that pentanucleotides 1, 2, 4 and 7 are essential for replication (10).  
 
 To test origin binding, we performed electromobility shift assays (EMSA).  
Affinity tagged MCPyV LT constructs were transfected into HEK 293 cells.  Forty-eight 
hours later, LT proteins were immunopurified and cleaved with TEV protease (Figure 
2.6B).  Various amounts of purified proteins were then incubated with a 32P-labeled PCR 
product encompassing all ten pentanucleotides and one of the two A/T tracts (Figure 
2.6A, EMSA probe).  Previous work with the SV40 Ori demonstrated that using Ori 
probes that lacked either the A/T rich tract or early palindrome region of the Ori revealed 
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a defect in double hexamer formation for T124A mutants (73).  We predicted that the 
T299A mutant would exhibit a similar double hexamer defect in similarly altered Ori 
probes; however, given that one of the key pentanucleotides required for MCPyV 
replication (#7) lies outside one of the two A/T rich tracts of the MCPyV Ori, it was 
impossible to directly copy the unique architecture of the artificial probes generated in 
that study (10,73,98).  Following these observations, we chose to omit one A/T tract but 
retain all ten pentanucleotide repeats in the hopes of seeing this phenotype.  In addition, 
the ATP analogue AMP-PNP was included to stimulate hexamer formation but inhibit 
ATPase activity, which would unwind the double-stranded probe (62).  Protein/DNA 
complexes were resolved on a non-denaturing polyacrylamide gel in TBE. 
 
 All mutant MCPyV LT proteins were able to bind the probe, albeit with different 
affinities.  The WT LT showed robust binding beginning at 1µg purified protein; probe 
binding was further enhanced when more LT was added (Figure 2.6C).  In contrast, the 
T297A mutant achieved maximal probe binding at 0.5µg, indicating a more robust 
affinity for this probe than WT.  This phenotype agrees with the previous observation that 
this mutant replicates plasmids with the MCPyV Ori to a high degree (Figures 2.3 and 
2.5).  On the other hand, the T299A mutant exhibited an attenuated affinity for the EMSA 
probe; only at the highest dose (1.5µg) was binding evident, and still not to the level of 
either WT or T297A LT proteins.  Our EMSA studies with T299A did not reveal single 
hexamers, which would migrate faster than the double hexamers binding our probe.  It is 
possible that T299A does not have a double hexamer defect like its SV40 homologue, or 
that the probe used in our study was not sufficiently small to reveal such a phenotype.  
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Native PAGE analyses of these proteins was unable to resolve this question (data not 
shown).  The technical limitations of our assay therefore preclude making any statements 
about the ability of these mutants to form single or double hexameric complexes. The 
attenuated binding phenotype for the T299A mutant, however, agrees with the 
observation that this mutant fails to replicate plasmids containing the viral Ori (Figures 
2.3 and 2.5) and agrees with what has been reported for SV40 LT T124A binding (99).  
 
2.3.5: MCPyV Phospho-mutant LT Proteins Exhibit Similar Unwinding and Helicase 
Activities 
 After initial binding of the viral Ori, polyomavirus LT proteins form two 
hexameric complexes that then untwist and unwind the origin DNA to form an initial 
bubble of single-stranded DNA (61,64,69).  To test these mutants for their ability to 
unwind a double-stranded Ori sequence, we generated a probe that contained both A/T 
tracts and the first eight pentanucleotide repeats (Figure 2.7A, Unwinding Probe).  This 
probe was generated by annealing two oligonucleotides which form a duplex with a four 
nucleotide overhang; this overhang was filled in with the Klenow fragment of DNA 
Polymerase and 32P-labeled dCTP, generating a double stranded probe with one labeled 
strand.  This probe was then incubated with purified MCPyV LT in conditions that 
promote ATPase activity.  Reactions were then stopped with the addition of SDS and 
EDTA, and the DNA was resolved on a non-denaturing polyacrylamide gel.  All LT 
constructs were able to unwind the probe (Figure 2.7B).  This result was helicase 
dependent, because an MCPyV LT mutant, E627A, that we have previously described 
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failed to unwind our probe (Figure 2.8) (14). The T297A mutant, which showed a high 
affinity for the Ori (Figure 2.6C) showed unwinding activity similar to WT LT; because 
WT LT’s activity was close to maximal unwinding in this assay (compare Boiled Control 
lane with WT LT lanes, Figure 2.7B) we are unable to say whether this mutant might 
have increased unwinding activity over WT activity.  We also tested whether MCPyV LT 
could unwind a mutated Ori sequence.  We introduced the Ori350 point mutation to 
pentanucleotide 7 in our assay; this mutation was reported by our lab and others to have 
partially abrogated replication due to reduced binding of LT to the origin (Figure 2.8) 
(10,92).  LT was still able to unwind this mutant sequence; this is likely because either 
the amount of LT protein used in our in vitro settings, or the extended reaction time (1hr) 
compared to the EMSA (20min) can compensate for the reduced binding of LT to this 
mutant Ori.     
 
 Following unwinding of the viral Ori, hexameric LT complexes then function as a 
DNA helicase that translocates along DNA to separate double stranded DNA (100).  To 
test this function, we employed a helicase assay that has been previously reported from 
our lab (14).  This assay uses a circular, partially duplex DNA substrate as a probe for LT 
helicase activity.  The probe does not contain MCPyV Ori sequences; DNA binding is 
mediated by non-specific interactions in the helicase domain.  The reaction is carried out 
with affinity purified LT proteins still immobilized to the affinity resin.  After washing 
bound proteins, half of the resin with bound LT protein was boiled in sample buffer and 
western blotted to detect protein levels (Figure 2.7C).  The other half of the resin was 
incubated with the 32P labeled probe in reaction buffer.  Helicase activity separates the 
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labeled oligonucleotide from the circular template, allowing the probe to migrate faster 
during electrophoresis (Figure 2.7D).   
 
 Our results show that the mutant MCPyV LT proteins had similar helicase activity 
as WT LT (Figure 2.7D).  In the conditions used, WT LT was able to maximally unwind 
the labeled probe; therefore we cannot conclude whether either of the mutants had 
enhanced helicase activity from this assay.  Interestingly, the T299A mutant, which failed 
to replicate the viral origin (Figure 2.5) did not have attenuated helicase activity in this 
experiment.  This has been previously reported for the T299A homologue in SV40 LT, 
indicating that this mutant’s helicase functions remain intact, and the block to replication 
is primarily due to an inability to bind the origin efficiently (Figure 2.6C) (94).  In 
contrast, the T297A mutant likely replicates to a high degree solely due to an increased 
affinity for the origin, as its unwinding and helicase activities were not markedly different 
from WT LT.  Taken together, our data indicate that T297 phosphorylation plays a direct 
role in binding of the origin, while T299 phosphorylation affects both origin recognition 
and possibly initial unwinding of the origin DNA, similar to its function in SV40 LT.  
 
2.4: DISCUSSION 
 Merkel Cell Polyomavirus is the first human polyomavirus linked to a human 
cancer.  As such, it has garnered a considerable amount of interest, especially with 
regards to its oncogenic potential and its causative role in MCC.  Much of the basic 
virology of MCPyV, in contrast, has been lacking, in large part due to the difficulty in 
propagating the virus and the lack of a natural host cell line.  Previous work from our lab 
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has established that MCPyV LT interacts with the host DNA damage response 
machinery, potentially to regulate viral genome replication (92).  Understanding how 
polyomavirus replication is regulated will be critical for understanding the very early 
steps of MCPyV-induced transformation and oncogenesis.   
 
 Phosphorylation has been a well-established mechanism of regulation for SV40 
LT activities, especially for genome replication.  In addition, MCPyV LT has a unique 
stretch of amino acids that is rich in serines and threonines, offering many new potential 
phosphorylation sites and therefore mechanisms of regulation.  To search for relevant 
sites in a relatively unbiased fashion, we performed a proteomic analysis of ectopically 
expressed MCPyV LT (Figure 2.1 and Table 2.1).  This analysis identified three 
threonines that are likely phosphorylated when MCPyV LT is expressed: T271, T297 and 
T299.  We generated alanine substitutions of these sites to probe their function.    
 
 T271 was immediately interesting to us for a variety of reasons.  It was 
independently identified in multiple peptides in both standard and titanium oxide 
purifications (Table 2.1), providing us with a high degree of confidence that this site is 
phosphorylated in cells.  More intriguing, this site is located in the unique region of 
MCPyV LT (aa 95-290).  It does not have any homologies to other polyomavirus LT 
proteins analyzed (Figure 2.1B).  We anticipate phosphorylation at this site may represent 
a novel function that MCPyV has acquired.  Efforts thus far, however, have not revealed 
what those functions may be.  The T271A mutant’s ability to bind Brd4 and activate the 
host DDR is similar to that seen for WT LT (data not shown).  Additionally, this mutant 
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was able to form replication foci and replicate plasmids containing the Ori almost as well 
as WT (Figures 2.3 and 2.5).  Additional experiments will be performed to identify its 
role in MCPyV infection.   
 
 T299, in contrast, is highly conserved among all polyomavirus LT proteins 
analyzed (Figure 2.1B).  This site is homologous to T124 in SV40 LT, which has been 
extensively studied for its role in regulating SV40 LT-mediated DNA replication.  
Alanine substitution of this site in SV40 LT completely abrogated replication.  
Biochemical analysis of T124A mutants showed that it had somewhat impaired double-
hexamer interactions and unwinding activity (68,73).  More importantly, its ability to 
unwind duplex Ori DNA was abrogated while basic helicase activity remained 
unperturbed (68).  In line with these findings, T299A in MCPyV LT also failed to 
replicate plasmids containing the viral Ori (Figure 2.5) and did not form replication foci 
(Figure 2.3).  This mutant had a reduced capacity to bind the viral Ori in EMSA 
experiments (Figure 2.6).  Although studies of the homologous LT mutant, T124A, in 
SV0 demonstrated that unwinding of the origin was attenuated, we were unable to 
reproduce this finding in our studies (94).  While is is possible that MCPyV LT behaves 
differently from other polyomavirus LT’s, we believe techcinal limitations in our hands 
are more likely responsible for not seeing this phenotype in MCPyV T299A LT.  Its 
helicase activity remained identical to wild-type (Figure 2.7D), which has been reported 
for T124A LT in SV40 (94).  Our EMSA studies did not indicate an attenuated double-
hexamer phenotype as shown by Barbaro and colleagues for SV40 LT (73), and the 
unwinding phenotype we observe is extremely subtle.  It is possible our experimental 
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conditions are not conducive for revealing these phenotypes, or (less likely) that T299 
phosphorylation behaves in a slightly different biochemical manner than T124 in SV40 
LT.  We conclude that phosphorylation of T299 is required for MCPyV LT to initiate 
replication of its genome in ways similar to T124 phosphorylation in SV40.   
 
 T297 was not well conserved among the polyomavirus LT proteins analyzed.  
Modeling of this site seemed to indicate that this residue might face and even interact 
with DNA when the LT OBD engages the viral genome (Figure 2.2B).  We speculated 
this site might have an impact on DNA replication.  Indeed, the T297A mutant had twice 
as many LT-positive nuclei exhibiting replication foci as WT LT (Figure 2.3D).  
Supporting this observation, Southern blotting of in cellulo replication products showed 
that this mutant replicated plasmids containing the viral origin to a very high degree 
(Figure 2.5).  Biochemical analyses revealed a strikingly robust affinity for the viral Ori 
(Figure 2.6), while unwinding and helicase activities remained largely unaffected (Figure 
2.7).  These data indicate that phosphorylation of this site would dramatically decrease 
LT’s capacity to bind the viral Ori, which would presumably limit its ability to initiate 
viral replication.  These observations are in line with our structural model (Figure 2.2) 
predicting that this site faces the OBD/DNA binding interface.  The negative charge of a 
phosphate moiety at this site would presumably clash with the negatively charged 
phosphate-backbone of DNA, leading to reduced DNA binding.  SV40 has also been 
reported to have phosphorylation sites that negatively impact replication.  
Phosphorylation at serines 120 and 123 was shown to have a negative effect on 
replication (74).  Threonine 297 may provide a similar regulatory function for MCPyV 
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LT.  It is possible that phosphorylation at a site neighboring the stimulatory threonine 
(124 for SV40 LT, 299 for MCPyV LT) may be a general feature of polyomavirus LT 
proteins to limit Ori recognition and to provide a brake for viral replication.  
 
 We attempted to generate phosphomimetic mutants (threonine to aspartate or 
glutamate) of these sites to probe these dynamics more closely; however, these mutants 
behaved just like alanine substitutions (data not shown).  Interestingly, a MCPyV LT 
expression construct containing both T297A and T299A mutations matched the T299A 
phenotype completely: it failed to form replication foci or replicate plasmids with viral 
Ori’s (data not shown).  The T297A mutation would allow for enhanced binding of the 
origin (Figure 2.6), but the T299A mutation, which likely acts at steps after Ori binding 
during initiation of replication, completely abrogated replication of this double mutant 
(data not shown).     
 
 Taken together, our data support a model where T299 and T297 phosphorylation 
act as antagonistic ON and OFF switches for replication, respectively. We would 
hypothesize that T299 is first phosphorylated to stimulate viral replication, while 
subsequent phosphorylation at threonine 297 would abrogate Ori recognition and 
presumably reduce viral genome replication, possibly in favor of late gene expression 
and/or packaging.  Phosphatases may also play a role, either removing phosphates from 
T299 to halt replication or from T297 to allow replication to continue.  Without 
antibodies specific for phosphorylation at these sites, it is difficult to track when these 
sites become phosphorylated during infection or to begin searching for the kinases that 
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add these marks during infection.  Analysis of the amino acid sequences of these sites 
offer some clues.  For SV40, cdc2/CDK1 was shown in vitro to be responsible for 
phosphorylation at T124, the homologue to MCPyV LT T299 (71).  The residues 
surrounding both MCPyV LT T299 and SV40 LT T124 (TPPK for both viruses, see 
Figure 2.1B) exhibit a classic cdc2/CDK1 consensus sequence (S-P-X-basic residue) 
(101).  Although it was not directly tested here, it is likely that cdc2/CDK1 plays a role in 
phosphorylating T299 during MCPyV infection.   Casein kinase II was also shown to 
phosphorylate nearby serine residues in SV40 LT in vitro, which played a role in SV40 
LT nuclear import (102-105).  Finally, ATM kinase has been shown to phosphorylate 
SV40 LT in this region as well, contributing to LT-mediated replication (81).  The 
threnonines T271 and T297 identified in this study do not exhibit homologies to the 
known consensus sequence of either of these kinases, indicating that other kinases are 
likely involved.  Finally, other MCPyV viral proteins, like sT antigen, 57kT antigen and 
ALTO (44), may affect when, where and how LT is phosphorylated during the viral life 
cycle.  These questions should be explored further as more reagents and cell lines become 
available for MCPyV studies. 
 
 One of the hallmark features of MCPyV LT in MCC is that the protein frequently 
becomes mutated such that it is expressed in a truncated fashion (9).  These truncations 
almost always delete the helicase domain and the OBD.  Interestingly, the three 
phosphorylation sites identified in this study are almost always omitted from the 
truncated proteins as well.  It has been hypothesized that LT becomes truncated to avoid 
replicating the integrated viral genome, which would presumably cause genomic 
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instability (3).  In line with this reasoning, at least one MCPyV related MCC tumor has 
been identified with a full-length LT protein but the integrated viral genome contains a 
mutated Ori that fails to support viral replication (9,10).  Given that mutation of T299 
completely abolishes LT’s capacity to replicate the viral origin, it is interesting to note 
that this mutation has never been observed in any of the MCC cases studied thus far.  It is 
possible that the OBD, helicase domain and/or extreme C-terminal domain contain 
additional activities beyond replication that are negatively selected out during MCC 
progression.  Our previous studies have indicated that the C-terminal half of MCPyV LT 
interacts with the p53 pathway to maintain cells in a stalled S-phase, which may be 
conducive to viral genome replication but antithetical to tumorigenesis (14).  Others have 
similarly postulated that the C-terminal domain contains activities beyond replication that 
are negatively selected during MCC oncogenesis (13).  Further investigation of this 
region of the protein may provide a broader and more comprehensive understanding of 
how MCPyV LT manipulates the host cell, and how these activities become disrupted 
during MCC tumorigenesis.   
 
2.5: FIGURES 
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TABLE 2.1 
 
TABLE 2.1: Phosphorylated peptides Identified by mass spectrometry.  Shown are 
the reconstructed peptides isolated by both the standard purification and titanium oxide 
enrichments after trypsin digest.  Confidence in identification is given as a probability.  
The residues in bold are the ones identified as having a mass value 80 daltons higher than 
predicted, indicating a phosphorylation modification.   
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FIGURE 2.1 
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Figure 2.1: Identification of MCPyV LT phosphorylation sites.  (A) Affinity-tagged 
MCPyV LT was transfected into HEK 293 cells.  Forty-eight hours post transfection, 
lysates from transfected (LT) or untransfected (Mock, M) cells were purified with IgG-
Sepharose beads.  Bound proteins were cleaved from beads with TEV protease, separated 
by SDS-PAGE and stained with Coommassie brilliant blue.  The band corresponding to 
MCPyV LT (*) was excised and analyzed by mass spectrometry.  L – Protein Marker 
ladder.  (B) Alignment of the N-terminal portion of various polyomavirus LT proteins.  
The three phosphorylated threonines identified by the proteomic analysis in (A) are 
indicated by the red asterisks (*).  Conserved residues are highlighted in blue (60% 
conservation). 
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FIGURE 2.2 
 
	  
Figure 2.2: Modeling MCPyV LT’s interaction with DNA.  (A) Phyre2 and PyMOL 
software was used to model the MCPyV LT protein origin binding domain (OBD) 
contacting DNA as reported by Harrison and colleagues (28).  The asterisks indicate the 
loop of the OBD that makes contacts with DNA.  (B) The structure modeled in (A) was 
extended to aa 290 and modeled using Phyre2 and PyMOLsoftware.  The model was 
rotated to match the orientation of the structure in (A).  T297 is highlighted in red and 
appears to face – and possibly contact – DNA.  (C) The same model in (B) was labeled to 
show T299, which appears to face away from DNA, possibly to interact with adjacent LT 
monomers or hexamers.  Valine 311 is labeled in all three structures to aid in comparison.  
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FIGURE 2.3 
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Figure 2.3: MCPyV LT phospho-mutant proteins form viral replicaiton foci at 
altered efficiencies.  (A-C)  C33A cells were co-transfected with an MCPyV Ori plasmid 
and the indicated MCPyV LT phospho-mutant.  Forty-eight hours post transfection, cells 
were fixed and stained for LT (green) and the indicated cellular factor (Red).  Nuclei 
were counterstained with DAPI.  Bar = 3µm.  (D) Nuclei stained positively for LT as 
shown in (A-C) were scored for the presence of viral replication foci (at least 150 LT 
positive nuclei were counted in triplicate per transfection).  Bar indicates standard 
deviation from the mean from at least three independent experiments.  Statistical 
significance was calculated against WT LT using a one-way ANOVA (*** p < 0.0001).   
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FIGURE 2.4 
 
FIGURE 2.4: MCPyV phospho-mutant LT proteins recruit cellular factors to the 
same degree.  Replication foci scored in Figure 2.3 A-C were assessed for colocalization 
of the indicated cellular factors.  Bar indicates standard deviation from the mean from 
three independent experiments.  A one-way ANOVA was performed to determine 
significance (** p < 0.001).     
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FIGURE 2.5 
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Figure 2.5: MCPyV LT phospho-mutant proteins replicate plasmids containing the 
viral Ori to differing degrees.  C33A cells were co-transfected with a MCPyV Ori 
plasmid and the indicated MCPyV phospho-mutant LT. Forty-eight hours post 
transfection cells were split and extracted for total cellular DNA or total proteins. (A) 
Southern blotting of whole genomic DNA.  Both the MCPyV Ori and MCPyV LT 
plasmids use the same vector backbone and are both recognized by the Southern blot 
probe.  15 µg of DNA was digested with BamHI and DpnI to detect replicated origin 
plasmid (Replicated Products, top); replicated Ori plasmid is indicated.  2 µg of DNA 
was digested with only BamHI to show equal loading (Input, bottom); Ori and LT 
plasmids are indicated.  The vector control plasmid for LT is almost identical in size to 
the Ori plasmid, causing both plasmids to co-migrate in the blot (asterisk, first lane, 
bottom panel).  (B) Total protein extracts were Western blotted to detect MCPyV LT and 
GAPDH.  Southern and Western blots are representative of at least three experiments.   
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FIGURE 2.6 
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Figure 2.6: MCPyV LT phospho-mutants bind the viral Ori with different affinities.  
(A) Schematic of the MCPyV Ori and the EMSA Probe.  Only one strand of DNA is 
shown for clarity. The MCPyV Ori sequence was cloned from the R17a isolate of 
MCPyV into a pcDNA4c vector (50).  This origin was used for replication assays (Figure 
2.3, 2.4, and 2.5).  Consensus GAGGC pentanucleotide repeats which are recognized by 
the OBD of LT are marked with arrows and numbered as was reported by Kwun et al. 
(10).  Arrows with dashed lines indicate imperfect pentanucleotides.  The EMSA Probe 
was generated by PCR amplification of the indicated region of the MCPyV Ori.  This 
PCR product was 5’ end-labeled with [32P-γ] ATP using T4 polynucleotide kinase 
(indicated by red asterisk).   (B) Western blot of purified MCPyV proteins (0.25µg) used 
in EMSA.  The buffer control contained residual TEV protease (also in LT samples).  (C) 
Electromobility shift assays were performed with the EMSA probe in (A) and increasing 
amounts of MCPyV wild type or phospho-mutant LT affinity purified from HEK 293 
cells.  Reactions with buffer and residual TEV protease served as a negative control (first 
lane).  Positions of free probe and LT bound probe are indicated.  Data in (B) and (C) are 
representative of at least three experiments.    
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FIGURE 2.7 
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Figure 2.7: MCPyV LT phospho-mutants have similar unwinding and helicase 
activities.  (A) Schematic of the Unwinding Probe.  The Unwinding Probe was generated 
by annealing two complimentary oligonucleotides spanning the indicated sequence.  The 
duplexed oligo contains a four-nucleotide overhang that was filled in by Klenow and 
[32P-α] dCTP so that only one strand was labeled.  The filled-in nucleotides are marked in 
bold, and the radiolabeled dCTP is indicated by an asterisk.  The MCPyV Ori sequence 
depicted in Figure 2.6A is shown for reference.  (B) Unwinding assays were performed 
with varying amounts of affinity purified MCPyV LT (wild-type or phospho-mutant).  
Samples without purified protein served as a negative control.  One sample was boiled to 
show the migration of unbound probe.  Data are representative of three independent 
experiments.  (C, D) Constructs expressing affinity tagged MCPyV wild-type or 
phospho-mutant LT were transfected into 293 cells.  Proteins were harvested 48 hrs post-
transfection and LT was immunopurified on IgG-conjugated beads.  Half of the beads 
with bound LT were boiled in sample buffer and resolved on an SDS-PAGE followed by 
Coommassie staining (C) while the remaining beads were used in the helicase assay (D).  
Beads incubated with 1% bovine serum albumin served as a negative control (BSA).  
Helicase reaction mix incubated at room temperature (Control) or at 95˚C for 5min 
(Boiled Control) served as controls for partially duplex and unwound substrate, 
respectively.  Data shown are representative of at least three independent experiments.   
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FIGURE 2.8 
 
FIGURE 2.8: Unwinding assay performed with a helicase mutant LT and a mutated 
Ori probe.  Unwinding assays were performed with both wild-type LT and the E627A 
mutation, which abolishes helicase activity.  In parallel, an origin probe with a mutation 
in the seventh pentanucleotide repeat which abolishes origin-dependent replication 
(Ori350) was also tested using wild-type MCPyV LT.  Data shown are representative of 
two repeats. 
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CHAPTER 3: PHOSPHORYLATION OF MERKEL CELL POLYOMAVIRUS 
LARGE T ANTIGEN AT SERINE 816 BY ATM KINASE INDUCES APOPTOSIS 
IN HOST CELLS 
 
 Dr. Jing Li was the primary investigator for this project, and was responsible for 
the design and execution of most of the experiments.  I assisted in screening various LT 
truncation and point mutants to show that the C-terminal half of LT was recognized by 
the phospho-Chk1 antibody (Figure 3.1 and data not shown).  I also designed and 
performed the CIP experiment to show that this cross-reactive antibody recognized a true 
phosphorylation mark, and helped confirm that S816 was the phosphorylation site (Figure 
3.2).  I later assisted in testing whether S816E was a phosphomimetic.  Dr. Xin Wang 
assisted in performing the in vitro phosphorylation assay, while Sabrina Tsang assisted 
with the ATM pulldown experiment (Figure 3.4).  All other experiments were performed 
by Jing.  I prepared the manuscript and made major contributions to the experimental 
design of the manuscript.     
 
 
 
Jing Li, Jason Diaz, Xin Wang, Sabrina H. Tsang, and Jianxin You. Phosphorylation of 
Merkel Cell Polyomavirus Large T Antigen at Serine 816 by ATM Kinase Induces 
Apoptosis in Host Cells. Journal of Biological Chemistry 2014; Epub Ahead of print 
DOI: 10.1074/jbc.M114.594895 © the American Society for Biochemistry and Molecular 
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3.1: CHAPTER SUMMARY 
 During the preparation of an earlier manuscript (Jing Li et al., Journal of Virology 
(2013) 87: 9173-88), we noticed that an antibody raised against phosphorylated serine 
345 of the cellular kinase Chk1 had cross reactive bands identical in size with ectopically 
expressed MCPyV LT constructs specifically retaining the C-terminus. We showed that 
this cross-reactivity was through a true phosphorylation mark sensitive to phosphatase 
treatment, and screened a number of candidate point-mutants to finally localize this mark 
to serine 816 of LT.  Since the cross-reactive antibody targeted a kinase involved in the 
DDR, we asked whether phosphorylation of S816 was mediated by DDR pathways.  
Pharmacological treatment to activate and suppress various arms of the DDR, coupled 
with in vitro binding and kinase assays, indicated that the double-strand break repair 
kinase ATM was likely the cellular kinase for S816 phosphorylation.  The c-terminal 
region of LT has been shown to have a growth-inhibitory effect, so we asked whether 
S816 phosphorylation contributed to this activity.  A clonogenic assay showed that the 
alanine mutant S816A LT partially rescued the growth arresting properties of MCPyV 
LT.  Analysis of molecular markers for apoptosis also showed less cell death with 
S816A.  This study uncovered a novel phosphorylation site for MCPyV LT and identified 
a candidate cellular kinase responsible for this modification while also implicating 
growth arrest and apoptosis as functional consequences of this activity.  
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3.2: INTRODUCTION 
 Merkel cell polyomavirus (MCPyV) is a recently identified polyomavirus that is 
associated with a highly aggressive skin cancer MCC (6,8). MCPyV is associated with 
approximately 80% of MCC cases (6,9,106). MCC metastasizes rapidly. It is one of the 
most aggressive skin cancers with an extremely high mortality rate of 33%, exceeding the 
rate of melanoma (107), and less than 45% five-year survival rate (108). The incidence of 
MCC has increased from 1.5 to 6 per million people between 1986 and 2006, and 
approximately 1500 new cases of MCC are diagnosed each year in the United States 
(109,110). Epidemiological surveys of MCPyV antibodies and sequencing analyses of 
healthy human skin have indicated that MCPyV may represent a natural component of 
the human skin micro-flora (19,21,22).  
 
 Like other polyomaviruses, MCPyV encodes a single early gene, the Tumor 
antigen.  The MCPyV Tumor antigen is multiply spliced into the Large Tumor antigen 
(LT), small Tumor antigen (sT), 57 kT, and ALTO (41,44). Similar to other 
polyomaviruses, the multi-functional MCPyV LT protein is involved in a variety of 
processes, including viral genome replication and host cell cycle manipulation 
(14,50,111).  
 
 MCPyV LT contains conserved features of other polyomavirus LT proteins, such 
as conserved region 1 (CR1), a DnaJ domain which interacts with Heat shock protein 70 
(Hsc70) family members, an LXCXE pRb binding motif, an OBD, and a 
helicase/ATPase domain required for viral DNA replication (9,41). The T antigens from 
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several polyomaviruses have oncogenic activity. Notably, the simian virus 40 (SV40) 
large and small T antigens can transform a variety of rodent and human cells (31,112). In 
addition, LT from SV40 as well as the human polyomaviruses JCV and BKV can bind to 
pRb and p53 tumor suppressor proteins (113-116). MCPyV LT can bind specifically to 
pRb (9,32). While there are two potential p53 binding motifs on the MCPyV LT C-
terminal domain, there appears to be no direct interaction between MCPyV LT and p53 
(13,26). Interestingly, the MCPyV genome is commonly clonally integrated into MCC 
tumor cell genomes. Almost all MCPyV LTs expressed from the integrated MCPyV 
genomes harbor non-sense mutations, which result in expression of a truncated large T 
that retains the N-terminal pRb binding motif but deletes the C-terminal DNA binding 
and helicase domains (9).  
 
 It has been postulated that these truncated LT proteins arise because replication of 
the integrated viral genome by full-length MCPyV LT may instigate a debilitating 
amount of DNA damage due to abortive replication at the integrated viral origin (9). The 
identification of a tumor with intact, full length LT but a mutated viral origin sequence 
supports this hypothesis (10). Later studies have since suggested that the C-terminal 
helicase domain may contain other functions that oppose tumorigenesis (13,14). Our 
previous work indicates that expression of full-length MCPyV LT activates a dramatic 
DDR that is antagonistic to tumorigenesis; this activity activates p53 and induces a 
growth-inhibition phenotype (14). Additionally, Cheng et al. reported that expression of 
the C-terminal 100 residues of MCPyV LT could inhibit the growth of several different 
cell types (13). These studies support a model where the C-terminal domain must be 
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deleted in tumor cells to both limit viral replication from the integrated viral genomes, 
and eliminate growth-arresting properties intrinsic to the C-terminal domain of LT. How 
the MCPyV C-terminal 100-residues accomplishes this growth-arresting function is not 
clearly understood.  
 
 In addition to being stimulated by MCPyV LT expression, work from our lab has 
shown that components of the host DDR are recruited to viral replication centers (49).  
These factors were necessary for supporting MCPyV genome replication (49), but their 
mechanism of action was not understood.  Protein phosphorylation of serines (S), 
threonines (T), and tyrosines is one of the most common methods for regulating protein 
function. Phosphorylation of SV40 LT on both serine and threonine residues plays an 
important role in regulating LT antigen function. Phosphorylation of SV40 LT S120 and 
S123 inhibits viral replication, while phosphorylation of T124 enhances replication by 
activating the DNA binding domain and stimulating double-hexamer activity 
(71,72,81,117,118). Phosphorylation of T701 is required for binding to the host FBW7 
gamma isoform, which regulates SV40 LT protein stability (119). The studies presented 
in Chapter 2 identified T271, T297 and T299 as phosphorylation sites on MCPyV LT.  In 
that study, we demonstrated that phosphorylation of T297 and T299 regulates MCPyV 
LT-mediated replication of the viral DNA. In this current study, we identify a novel 
MCPyV LT phosphorylation site at S816.  We demonstrate that this site is 
phosphorylated by ataxia telangiectasia mutated (ATM) kinase, a key component of the 
host DDR primarily activated by dsDNA breaks (DSBs) (120). Activation of ATM 
kinase by etoposide increases MCPyV LT phosphorylation at S816.  In contrast, Ataxia-
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telangiectasia and Rad3 related (ATR) kinase was unable to robustly phosphorylate 
MCPyV LT. Expression of wild-type MCPyV LT inhibits cell proliferation and also 
induces several cell lines to undergo apoptosis. Expression of the serine to alanine 
substitution mutant MCPyV LT S816A partially rescues this growth inhibition and also 
inhibits the induction of apoptosis. This report reveals that MCPyV LT is a substrate of 
ATM kinase, and that phosphorylation at S816 contributes to the regulation of host cell 
proliferation and apoptosis.  
 
3.3: RESULTS 
3.3.1: MCPyV LT is Phosphorylated at S816   
 In our previous study, we found that either MCPyV infection or transfection of 
MCPyV genomes into cells activated both ATM and ATR kinases, while ectopic 
expression of just MCPyV LT primarily induced the ATR-Chk1 DDR pathway in U2OS 
cells (14). Interestingly, in these immunoblotting experiments we also discovered that the 
anti phospho-Chk1 S345 antibody not only detected phospho-Chk1 S345 but also 
recognized protein bands with molecular weights that match those of transfected LT 1-
817, LT 212-817, GFP-LT 441-817 or GFP-LT 1-817, respectively (Figure 3.1A and B, 
bands with an arrow). This cross-reactivity was observed for all MCPyV LT truncation 
mutants retaining the carboxyl terminal ~400 amino acids (Figure 3.1A and B). These 
cross-reactive bands were also detected in C33A and HeLa cells (data not shown). This 
antibody also recognized another cross-reactive band of about 120 kD in all samples, 
regardless of LT expression (Figure 3.1B, band marked with an asterisk).  SV40 LT also 
activated phospho-Chk1 S345 in U2OS cells (14), but there were no cross-reactive bands 
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detected in the SV40 LT sample (Figure 3.1A). Since the cross-reactive bands (marked 
with an asterisk) had similar molecular weights as the ectopically expressed LTs in those 
samples, we suspected that the anti-pChk1 S345 antibody specifically cross-reacts with 
MCPyV LT.  
  
To confirm that this cross-reaction was mediated by a true phosphorylation 
modification, lysates from U2OS cells transfected with pcDNA4C-MCPyV LT were 
treated with or without calf-intestinal alkaline phosphatase (CIP) for 30 minutes, and 
analyzed by Western blot. As shown in Figure 3.2A, expression of LT 1-817 activates a 
robust phospho-Chk1 S345 signal in U2OS cells, and there is again a cross-reactive band 
with a molecular weight around 110 kD that matches the size of full-length MCPyV LT.  
Treatment with CIP significantly diminished both the phospho-Chk1 and the 110 kD 
cross-reactive signal (marked with an arrow) in the cell lysate (Figure 3.2A). 
Interestingly, the other cross-reactive band of about 120 kD (marked with an asterisk) 
was also diminished.  This result suggests that the phospho-Chk1 S345 antibody 
recognizes a true phosphorylation modification on both the 110 kD and 120 kD cross-
reactive bands.  
 
Chk1 is phosphorylated by ATR kinase at S345 in a canonical S/T-Q epitope that is 
commonly targeted by ATM and ATR kinases.  Assuming the cross-reactive band similar 
to transfected LT was indeed MCPyV LT, the data from Figure 3.1 suggested that the 
phosphorylation site was within the C-terminal 400 amino acids.  We compared the 
epitope recognized by the phospho-Chk1 S345 antibody with the C-terminal sequence of 
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MCPyV LT and generated alanine substitutions of several potential phosphorylation 
sites. These point mutants were transfected into U2OS cells and immunoblotted with the 
pChk1 S345 antibody. Out of all the sites analyzed, we found that mutagenesis of S816 
alone abolished MCPyV LT cross reactivity with the phospho-Chk1 S345 antibody 
(Figure 3.2B and data not shown).  The 120 kD cross-reactive band was unaffected when 
cells were transfected with this mutant LT.  Taken together, these data demonstrate that 
MCPyV LT is phosphorylated at S816, and that this phosphorylation is specifically 
recognized by the pChk1 S345 antibody.  The 120 kD band (marked with an asterisk) is 
likely a cellular phospho-protein that is also recognized by this antibody; however, we 
chose to focus the remainder of our study on the phosphorylation of MCPyV LT at S816.    
  
3.3.2 Activation of ATM Stimulates MCPyV LT S816 Phosphorylation  
 Having identified S816 as a phosphorylation site of MCPyV LT, we next sought 
to determine which kinase(s) or kinase pathway(s) was responsible for this modification. 
Our previous data showed that MCPyV virus infection and MCPyV genome transfection 
activate both ATM and ATR DNA damage response pathways. In contrast, ectopic 
expression of MCPyV LT alone predominantly activates ATR and only weakly activates 
ATM (14,49). Additionally, we have reported that components of the host DDR 
pathways are recruited to viral replication centers, and that their activity is required for 
efficient replication (49). We wondered whether components of these DDR pathways 
could be responsible for LT S816 phosphorylation. 
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 We first used etoposide or UV light to activate either ATM or ATR pathways, 
respectively, and tested whether phosphorylation of LT was altered. U2OS cells were 
transfected with pcDNA4C (Vec) or pcDNA4C-MCPyV LT.  Forty-four hours post 
transfection, cells were treated with either 4 µM etoposide for another 4 hours or treated 
with 10 J UVC light. The cells were then harvested for Western blot analysis. As shown 
in Figure 3.3A, expression of LT induced a mild activation of both ATM S1981 
phosphorylation and Chk1 S345 phosphorylation, a surrogate of ATR activation 
(compare lane 4 to lane 1 in Figure 3.3A). Etoposide treatment, which primarily activates 
ATM kinase, induced dramatic activation of ATM S1981 phosphorylation as well as LT 
phosphorylation at S816 (Figure 3.3A, lane 5). In contrast, UV light treatment, which 
predominantly activates ATR, caused a much smaller degree of ATM phosphorylation 
and very little activation of LT S816 phosphorylation compared to DMSO treatment 
(Figure 3.3A, compare lane 6 to lane 4).  These results demonstrated that activation of the 
host ATM DDR pathway could stimulate phosphorylation of MCPyV LT at S816. 
Robust phosphorylation of Chk1 S345 was seen with both etoposide and UV treatments, 
indicating either that ATR was activated in both settings, or that the robust activation of 
ATM during etoposide treatment allowed it to phosphorylate Chk1 through cross talk 
(121-124). 
  
3.3.3: Inhibition of ATM Prevents MCPyV LT S816 Phosphorylation  
 We next sought to determine which component(s) of the host DDR was 
responsible for phosphorylating MCPyV LT.  We tested a panel of chemical inhibitors to 
screen for the possible kinases that phosphorylate MCPyV LT at S816. U2OS cells were 
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transfected with pcDNA4C (Vec) or pcDNA4C-MCPyV LT. Forty-four hours later, cells 
were treated with DMSO, Wortmannin, NU 6027, NU 7441, KU 55933, AZD 7762, or 
caffeine for another six hours. The cells were harvested for Western blot analysis. As 
shown in Figure 3.3B, the expression level of LT is constant with different drug 
treatments. MCPyV LT transfected cell lysates show phosphorylated MCPyV LT S816 
bands at around 110 kD; however, the band density changes with various drug treatments 
(Figure 3.3B). Caffeine, which inhibits both ATM and ATR, reduced phosphorylation of 
LT S816 to a small extent (Figure 3.3B). Wortmannin, which acts as a broad PI3K 
inhibitor that inhibits DNA-PK, ATM, and ATR, efficiently inhibited MCPYV LT S816 
phosphorylation (Figure 3.3B). On the other hand, the ATR inhibitor NU 6027, the DNA-
PK inhibitor NU 7441, and the Chk1 inhibitor AZD 7762, did not affect LT 
phosphorylation (Figure 3.3B). These results suggests that the ATM pathway was likely 
important for the LT S816 phosphorylation.  Further supporting this notion, the ATM 
inhibitor KU 55933 caused dramatically reduced LT S816 phosphorylation (Figure 3.3B). 
These experiments were repeated in C33A cells with similar results (data not shown). 
Taken together, these data suggest that ATM is likely the kinase that phosphorylates 
MCPyV LT at S816. 
  
3.3.4: ATM Kinase Binds and Phosphorylates MCPyV LT at S816 In Vitro  
 We then performed in vitro phosphorylation experiments to more directly confirm 
that ATM kinase phosphorylates MCPyV LT at S816.  An IgG-IgG-TEV (IIT) affinity 
tag, comprising two IgG binding domains and a tobacco etch virus (TEV) cleavage site, 
was subcloned in-frame with wild type and S816A mutant MCPyV LT for affinity 
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purification (See Materials and Methods and (50)).  IIT affinity tagged wild type MCPyV 
LT or S816A LT was purified from 293 cells and treated with CIP to remove 
phosphorylation modifications. In parallel, U2OS cells were stimulated with etoposide to 
activate the host DDR, and either ATM or ATR kinases were immunoprecipitated from 
nuclear extracts (Figure 3.4A). ATM or ATR was then immunoprecipitated and 
immobilized on sepharose beads and incubated with radiolabeled ATP and equal amounts 
of either wild type LT or LT S816A protein in kinase reaction buffer. Only wild type LT 
incubated with immunopurified ATM demonstrated significant phosphorylation; 
incubation with ATR did not show detectable activity above background (Figure 3.4A). 
This was true when the in vitro phosphorylation reaction was performed either at room 
temperature or at 37˚C.  The S816A LT was not phosphorylated by either ATM or ATR 
kinases, regardless of temperature (Figure 3.4A).  We also confirmed that LT could 
interact with ATM by pulling down ATM kinase from U2OS nuclear extracts using 
immobilized, bacterially derived LT (Figure 3.4B).  This binding was clearly evident 
even with a relatively small amount of LT (Figure 3.4B, compare GST with GST-LT in 
the CBB stain).  These data, together with the kinase inhibitor screen shown in Figure 
3.3B, strongly suggest that ATM is the major kinase that phosphorylates MCPyV LT at 
S816. 
  
3.3.5: Prevention of MCPyV LT S816 Phosphorylation Partially Rescues the MCPyV LT 
Growth Inhibition Effect  
 We next sought to better understand the physiological function of the ATM-
mediated MCPyV LT S816 phosphorylation. We were unable to find defects in genome 
	   66	  
replication or viral gene transcription for MCPyV LT S816A (data not shown). Our 
previous study demonstrated that the C-terminal portion of LT activates p53 and 
promotes growth inhibition (14). Cheng et al. also reported that the C-terminal 100 amino 
acids of MCPyV LT have a cell growth inhibition effect (13). The underlying mechanism 
of these findings was not completely established.  Since the C-terminal domain of 
MCPyV LT was sufficient for DDR activation (14), and because S816 lies within the C-
terminal 100-amino acids region of MCPyV LT, we asked whether S816 phosphorylation 
played a role in the cellular growth inhibition function of the MCPyV LT C-terminus. We 
generated C33A cells stably expressing wild type MCPyV LT, S816A LT, or Cherry-
LacI as a negative control. Using these cell lines, we performed a clonogenic assay to 
detect the long-term effect of MCPyV LT and MCPyV LT S816A on cellular 
proliferation. The same number of C33A stable cells were seeded in 6-well dishes and 
cultured for 10 days under puromycin selection. As shown in Figure 3.5, the Cherry-LacI 
stable cell line forms a large number of colonies.  As reported previously (14), expression 
of wild type MCPyV LT caused a significant inhibition of cell growth, resulting in 
drastically reduced colony number after selection (Figure 3.5).  S816A LT partially 
reversed this LT growth inhibition phenotype, allowing more colonies to be formed after 
the extended culture period (Figure 3.5). This result suggests that blocking MCPyV LT 
S816 phosphorylation can partially rescue the LT growth inhibition activity, 
demonstrating the impact of MCPyV LT S816 phosphorylation on cellular proliferation. 
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3.3.6: MCPyV LT S816A Induces Less Apoptosis Than Wild-Type MCPyV LT  
 We consistently observed that transfection of the MCPyV LT S816A construct 
led to less cell death than the wild-type MCPyV LT construct. The results of the 
clonogenic assay also suggested that S816A LT might induce less cell death than wild 
type MCPyV LT. We therefore tested both proteins for their ability to induce apoptosis. 
We performed Annexin V staining to detect cells that express phosphatidylserine (PS) on 
the cell surface, which is an early marker of apoptosis (125).  GFP tagged MCPyV LT or 
MCPyV LT S816A was transfected into C33A cells.  The transfected cells were stained 
with PE conjugated Annexin V at 24 hours post transfection. Cells were then fixed and 
nuclei were counterstained with DAPI. At this time point, about 0.2% of vector 
transfected cells have Annexin V staining, while 6.5% of MCPyV LT transfected cells 
show positive Annexin V staining; however, only 3.8% of MCPyV LT S816A transfected 
cells were Annexin V positive (Figure 3.6A and B). This result shows that MCPyV LT 
S816A has decreased ability to induce cell death than MCPyV LT. Flow-cytometry 
analysis also detected slightly more apoptotic cells with sub-G1 fraction in wild type 
MCPyV LT transfected cells than in LT S816A samples (data not shown). These results 
are consistent with the observation that MCPyV LT can more potently inhibit cell 
proliferation than S816A LT (Figure 3.5). 
 
 To examine the differential activation of cell death by wild type MCPyV LT and 
S816A LT at the molecular level, we performed Western blotting analyses to detect the 
apoptotic marker Caspase-3 and Poly (ADP-ribose) polymerase 1 (PARP1). Caspase-3 is 
activated in both the extrinsic (death ligand) and intrinsic (mitochondrial) apoptotic 
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pathways (126,127). In the intrinsic activation pathway, cytochrome-c from the 
mitochondria works in combination with caspase-9, apoptosis-activating factor 1 (Apaf-
1), and ATP to process pro-Caspase-3 (128-130). Proteolytic processing of the inactive 
zymogen into p17 and p12 fragments activates Caspase-3. PARP1 is involved in the 
repair of DNA damage by adding poly (ADP-ribose) polymers onto a variety of 
substrates in response to various cellular stresses (131). PARP1 is also a substrate for 
caspases; during the execution phase of apoptosis, PARP1 is specifically proteolyzed by 
Caspase-3 to produce a 24 kD N-terminal DNA binding domain (DBD) and a 89 kD C-
terminal catalytic fragment (132). Cleavage of PARP1 by caspases is considered to be a 
hallmark of apoptosis (133,134). 
 
 We transfected either C33A or HeLa cells with pcDNA4C (Vector), pcDNA4C-
MCPyV LT, or pcDNA4C-MCPyV LT S816A. Cells were harvested at 30 hours post 
transfection and analyzed by Western blotting. As shown in Figure 3.6C and D, 
expression levels of LT and LT S816A are similar.  Vector transfected cells did not 
exhibit cleaved Caspase-3 and only showed background level of cleaved PARP1, 
indicating little apoptosis in these conditions (Figure 3.6C and D). Wild type LT 
transfected cells have less intact PARP1, but more cleaved PARP1 as well as more 
cleaved Caspase-3 than the empty vector samples, confirming the induction of apoptosis 
(Figure 3.6C and D). In contrast, the levels of cleaved PARP1 and cleaved Caspase-3 in 
the MCPyV LT S816A transfected cells were reduced to nearly the vector control level 
(Figure 3.6C and D). These results are consistent with the observation that MCPyV LT-
positive cells are more likely to undergo apoptosis than MCPyV LT S816A-positive cells 
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(Figure 3.6A and B). These results support the rescue of cell growth inhibition phenotype 
seen in the clonogenic assay (Figure 3.5). We also tested whether the S816E mutant 
would act as a phosphomimetic, and presumably induce more apoptosis.  Unfortunately, 
LT S816E behaved identically to the alanine mutant and therefore was not a viable 
phosphomimic (data not shown); this phenomenon has occasionally been reported for 
other phosphoproteins, including SV40 LT and MCPyV LT at other phosphosites 
(135,136). Taken together, these data suggest that phosphorylation of LT at S816 
contributes to growth-arrest and apoptotic induction mediated by the C-terminal domain.    
 
3.4: DISCUSSION 
 Most MCPyV-related MCC tumors examined thus far contain clonally integrated 
MCPyV genomes, which express truncated LT proteins that omit the C-terminal domain 
(9). This observation suggests a strong selective pressure to eliminate the C-terminal 
region of MCPyV LT during MCC tumor development.  These tumor specific mutations 
do not affect LTs pRb binding domain or DnaJ domain (6).  In fact, these LT mutants 
even have an increased affinity for pRb (26).  Work from our lab and others suggest that 
the C-terminal domain of MCPyV LT might be negatively selected during tumorigenesis 
to eliminate growth inhibitory properties encoded in this region (13,14).   
 
 Our previous report shows that inhibition of cellular proliferation by the C-
terminal half of MCPyV LT is linked to its ability to activate the host DDR pathways 
(14). In those experiments, we consistently detected cross-reactivity of the monoclonal 
anti-pChk1 S345 antibody when MCPyV LT constructs were expressed.  In this report, 
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we explored the nature of this cross-reactivity. The cross-reactive bands correlated with 
the sizes of ectopically expressed full-length MCPyV LT or LT C-terminal mutants 
(Figure 3.1), and were sensitive to phosphatase treatment (Figure 3.2A), making us 
suspect that this antibody recognized a phosphorylation modification on MCPyV LT.  
This cross-reaction seemed to be localized to the C-terminal half of the protein (Figure 
3.1).  Alanine substitutions of candidate serines and threonines further identified S816 as 
the target of phospho-Chk1 S345 cross-reaction (Figure 3.2B).  
 
 Our previous studies demonstrated that MCPyV LT activates the host DDR 
proteins, which are recruited to actively replicating viral genomes (14,49). The cross-
reactive phospho-Chk1 S345 antibody was generated against Chk1 phosphorylated at 
serine 345, an ATR kinase phosphorylation site. We therefore asked whether the DDR 
kinases were responsible for the phosphorylation of MCPyV LT at S816.  Activation of 
ATM kinase with etoposide caused dramatic stimulation of MCPyV LT phosphorylation. 
On the other hand, UV treatment, which predominantly activates the ATR pathway, had 
little stimulating effect on MCPyV LT S816 phosphorylation (Figure 3.3A). A screen 
with multiple DDR kinase inhibitors further supported the hypothesis that ATM kinase 
was the predominant member of the DDR pathways responsible for this modification 
(Figure 3.3B).  In vitro phosphorylation of MCPyV LT with immunopurified ATM and 
ATR confirmed that ATM phosphorylates MCPyV LT at S816, but ATR cannot (Figure 
3.4A).  Additional pull-down experiments suggested that ATM and LT can indeed 
interact (Figure 3.4B). Together with our published results (14,49), this present study 
suggests that MCPyV is not only able to induce DDR in cells but can also take advantage 
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of this DDR activity and recruit a cellular DDR kinase, ATM, to phosphorylate its own 
LT at S816. 
 
We next sought to understand the physiological role of this phosphorylation mark.  
Although S816 lies C-terminal to the helicase domain, no effects were seen on viral 
genome replication or transcription (data not shown). We therefore asked whether LT 
S816 phosphorylation contributes to the growth inhibitory activity that was localized to 
the final 100 residues of this protein (13).  Interestingly, the growth inhibitory effect seen 
with wild type LT was partially reversed with LT S816A in a clonogenic assay (Figure 
3.5). The cellular proliferation phenotype was supported by an analysis of apoptosis 
during LT expression. Annexin V staining and Western blot analyses of Caspase-3 and 
PARP1 cleavage showed that S816A LT induced less apoptosis in transfected cells 
(Figure 3.6). These results demonstrated that the ATM-mediated phosphorylation of 
MCPyV LT at S816 contributes to a mechanism that inhibits cellular proliferation by 
inducing cellular death.  
 
Although this study establishes a direct functional interaction between ATM 
kinase and MCPyV LT, the precise role for this interaction remains elusive.  ATM is a 
serine/threonine protein kinase that is recruited to and activated by DNA double-strand 
breaks to phosphorylate several key cellular proteins that initiate the activation of the 
DNA damage checkpoint (137-139).  This checkpoint activation results in the 
phosphorylation and activation of p53, which in turn up-regulates the expression of key 
cellular factors involved in cell cycle arrest, DNA repair, and apoptosis (137-139).  The 
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cell proliferation effects reported here when MCPyV LT is expressed could therefore be 
partially due to ATM activity and represent a host response to foreign DNA replication; 
indeed, the effects of blocking MCPyV LT S816 phosphorylation on cell proliferation are 
modest and S816A LT was unable to fully rescue the proliferative defect in C33A cells 
stably expressing LT (Figure 3.5), indicating that S816 phosphorylation-independent 
mechanisms are at play.  
 
Our previous report and current study show that transfected LT only induces a 
very low level of ATM activation (Figure 3.3A and (14)). In contrast to transfected LT 
alone, infection with MCPyV virions or transfection of viral genomes robustly activates 
ATM (14); additionally, LT protein levels increase over time in these settings (data not 
shown). During true infection, therefore, the ATM-mediated MCPyV LTS816 
phosphorylation may lead to a more robust cell-cycle arrest and apoptotic phenotype, 
which may be advantageous in dispersing newly formed virions late in infection. 
Alternatively, this ATM-mediated MCPyV LT S816 phosphorylation and associated 
apoptotic activities may represent a host antiviral defense mechanism for eliminating 
MCPyV infected cells. 
 
It is also important to note that our study only examined LT when it is expressed 
alone. Whether LT phosphorylation is altered or temporally regulated when co-expressed 
with other viral proteins like sT, 57kT, or ALTO remains to be explored.  Our previous 
study established the DDR machinery as critical for LT mediated viral replication (49).  
This study further establishes an intimate interaction between MCPyV infection and the 
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host DDR, revealing how activation of a host DDR by MCPyV is then utilized by the 
virus to carefully orchestrate key events in host cells. Future studies will investigate the 
downstream events of MCPyV LT S816 phosphorylation by identifying the cellular 
proteins that may recognize this phosphorylation event. The identification of the S816 
phosphorylation site and the commercial availability of an antibody recognizing this 
modification provide valuable tools for advancing our understanding of MCPyV-host 
interactions.   
 
3.5: FIGURES 
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FIGURE 3.1 
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FIGURE 3.1: Anti phospho-Chk1 S345 antibody cross-reacts with MCPyV LT. (A) 
U2OS cells were transfected with pcDNA4C (Vector), pcDNA4C encoding Xpress 
tagged MCPyV LT molecules as indicated, or pTIH encoding SV40 LT. At 36 hours post 
transfection, cells were lysed and immunoblotted with the indicated antibodies. Arrows 
indicate cross-reactive bands corresponding to the molecular weight of the transfected LT 
molecule.  (B) U2OS cells were transfected with pEGFPC1 (Vector), or pEGFPC1 
encoding MCPyV LT molecules as indicated. At 36 hours post transfection, cells were 
lysed and immunoblotted with the indicated antibodies. Arrows denote cross-reactive 
bands matching the molecular weight of the transfected LT molecules as indicated in (A). 
Asterisks (*) indicate an additional cross-reactive band present in U2OS cells regardless 
of LT expression.   
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FIGURE 3.2 
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FIGURE 3.2: MCPyV LT is phosphorylated at S816. (A) U2OS cells were transfected 
with pcDNA4C vector (Vec) or pcDNA4C-MCPyV LT. Forty-eight hours post 
transfection, cells were treated with or without Calf-intestinal alkaline phosphatase (CIP) 
and analyzed by Western blot. Asterisk and arrow indicate cross-reactive bands as 
described in Figure 3.1.  (B) U2OS cells were transfected with pcDNA4C (Vector), 
pcDNA4C-MCPyV LT1-817 (wild type LT), or pcDNA4C-MCPyV LT 1-817 S816A 
(LT S816A). Forty-eight hours post transfection, cells were harvested and proteins were 
analyzed by Western blot with the indicated antibodies. Asterisk and arrow indicate 
cross-reactive bands as described in Figure 3.1. 
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FIGURE 3.3 
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FIGURE 3.3: ATM kinase phosphorylates MCPyV LT at S816. (A) U2OS cells were 
transfected with pcDNA4C vector (Vec) or pcDNA4C-MCPyV LT (LT). At forty-four 
hours post transfection, cells were treated with 4 µM etoposide for 4 hours or 10J UVC 
light.  Cells were then harvested and analyzed by Western blot with the indicated 
antibodies. Asterisk and arrow indicate cross-reactive bands as described in Figure 3.1. 
(B) U2OS cells were transfected with pcDNA4C (Vec), or pcDNA4C-MCPyV LT1-817 
(LT). At 44 hours post-transfection, cells were treated with DMSO, 20 µM Wortmannin, 
20 µM NU6027, 1 µM NU7441, 10 µM KU55933, 10 nM AZD7762, or 10 mM Caffeine 
for 6 hours.  Then cells were harvested and proteins were analyzed by Western blot with 
indicated antibodies. Asterisk and arrow indicate cross-reactive bands as described in 
Figure 3.1. 
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FIGURE 3.4 
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FIGURE 3.4: ATM can bind and phosphorylate LT in vitro.  (A)  In Vitro 
phosphorylation of MCPyV LT S816 by ATM. Affinity-tagged MCPyV LT or MCPyV 
LT S816A was purified from 293 cells and treated with CIP. ATM and ATR proteins 
were immunoprecipitated from U2OS cells which had been treated with 4 µM etoposide 
for 4hr. Purified LT was then incubated with purified ATM or ATR in kinase reaction 
buffer supplemented with [γ-32P] ATP.  Reactions were performed either at room 
temperature (RT) or 37˚C for 30min. Reactions were separated by SDS-PAGE and then 
either dried and exposed for autoradiography (top) or Western blotted for MCPyV LT 
(bottom, right). Immunopurified ATM and ATR proteins were Western blotted with the 
indicated antibodies (bottom, left).  (B) GST-LT pull-down of ATM. U2OS nuclear 
extracts were mixed with either immobilized, bacterially-derived GST or GST-LT 
protein. Input nuclear extract and pull-down samples were immunoblotted with anti ATM 
antibody (top). GST or GST-LT eluted from the glutathione resin was separated by SDS-
PAGE and stained with Coomassie Brilliant Blue (CBB) (bottom).  “L” – molecular 
weight ladder.  “−” – empty lane. 
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FIGURE 3.5 
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FIGURE 3.5: C33A cells stably expressing MCPyV LT S816A form more colonies 
than cells stably expressing wild-type LT. C33A cells stably expressing Cherry-LacI, 
MCPyV LT or MCPyV LT S816A were seeded at 5000 cells/well in a 6 well plate. Cells 
were cultured for 10 days with 0.625 µg/ml puromycin. Colonies were then fixed with 
methanol and stained with methylene blue.  Data shown are representative of at least 
three experiments. 
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FIGURE 3.6 
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FIGURE 3.6: MCPyV LT induces more apoptosis than LT S816A. (A) C33A cells 
were transfected with pEGFPC1 (Vector), pEGPFC1-MCPyV LT, or pEGFPC1-MCPyV 
LT S816A. Twenty-four hours later, cells were stained with Annexin V-PE and DAPI.  
Images are representative of at least three experiments.  Bar, 10 µm.  (B) The percent of 
GFP positive cells with Annexin V staining was quantified from approximately 100 cells. 
The mean and standard deviation (SD) was calculated from three cover slips. (C and D) 
C33A (C) and HeLa (D) cells were transfected with pcDNA4C (Vector), pcDNA4C-
MCPyV LT, or pcDNA4C-MCPyV LT S816A. Cells were harvested at thirty hours post 
transfection and cell lysates were analyzed by Western blot with the indicated antibodies.  
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CHAPTER 4: MERKEL CELL POLYOMAVIRUS LT AND ST 
COOPERATIVELY REGULATE THE VIRAL LATE PROMOTER 
 
 This chapter presents preliminary work elucidating how the MCPyV late 
promoter is regulated by both LT and sT.  I am the primary investigator and performed 
all of the experiments.  The NCCR reporter plasmids used in Figures 4.2 – 4.5 were 
constructed by Dr. Jing Li.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A preliminary manuscript of this work is in preparation.   
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4.1 SUMMARY 
 The work presented in Chapter 2 identified a threonine phosphorylation at T271 
of MCPyV LT, but established that T271 phosphorylation was not important for viral 
replication.  To test whether T271 phosphorylation is important for regulation of MCPyV 
promoters, transcriptional reporter constructs were generated by fusing the MCPyV 
NCCR to a luciferase gene such that protein expression would be controlled by the native 
early or late promoter.  Preliminary results using these NCCR reporter constructs showed 
that the wild-type LT could stimulate luciferase expression from the late promoter, but 
only when sT was also expressed.  The T271A mutant behaved identically to wild-type 
LT.  Interestingly, sT expression activated both Early and Late NCCR reporter constructs 
to a small degree.   The dependence of LT on sT co-expression for late promoter 
activation has not been previously reported in other polyomaviruses.  Follow up 
experiments showed that sT’s ability to stabilize LT expression did not play a major role 
in this co-operative activation phenotype.  These NCCR constructs can presumably be 
replicated by LT as they retain the viral Ori (see Chapter 2); therefore, increased 
luciferase activity could be explained by an increase in reporter copy number.  To address 
this concern, I examined two phosphomutant LTs (T297A and T299A, see Chapter 2) as 
well as an NCCR construct with a defective origin (Ori350, previously reported in (10)).  
The T297A mutant, which exhibits robust replication from the viral Ori, stimulated 
transcription just as well as wild-type LT.  The T299A LT mutant, which has an 
abrogated replication phenotype, and the Ori350 NCCR mutant, which also supports very 
low levels of replication, had attenuated transcriptional activation.  These results 
established that MCPyV replication and/or binding of the NCCR by LT is important for 
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stimulating the Late promoter.  Finally, examination of the isolated Late promoter with 
the rest of the NCCR, including the Ori, removed showed that LT expression actually 
represses this promoter, highlighting the importance of an intact MCPyV Ori sequence 
for LT-mediated stimulation of the late promoter.  These results present a model where 
LT expression negatively regulates the Late promoter prior to replication, and then 
robustly stimulates this promoter after binding to the NCCR and initiating replication.  
Interestingly, this post-replication activation by LT requires sT co-expression, revealing a 
synergistic interaction not exhibited by other polyomaviruses.   
 
4.2 INTRODUCTION 
 MCPyV is associated with a large majority of MCC, a rare and highly aggressive 
cancer of the dermis (3,6,8,23).  MCPyV-associated tumors exhibit a dependence on the 
expression of the viral oncogenes LT and sT; knockdown of these proteins cause MCC 
tumors to be rapidly cleared in a mouse xenograph model (32,33).  MCPyV associated 
cancers are therefore similar to papillomavirus associated cancers, where high expression 
of oncogenic viral proteins drive tumor progression (11,12).  Unlike papillomaviruses, 
however, the regulation of MCPyV oncogenes has not been well studied, either in a 
natural infection setting or in MCC cell lines.  Similarly, MCPyV research has faced the 
difficulty of finding cell lines that can efficiently propagate the virus; this difficulty 
largely stems from a lack of knowledge of the cellular environment that supports 
activation of either the early genes, which are necessary for replication of the viral 
genome, or the late genes, which consist of the viral capsid proteins required for 
generating new virions. To date, the mechanisms by which the MCPyV early and late 
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genes are regulated have not been elucidated.  Increasing our knowledge of viral 
transcription from both of these promoters will help us better understand MCPyV 
associated oncogenesis, and may also provide clues or even tools for more efficiently 
propagating fully functional virus for better studies of natural infection. 
  
 Like other polyomaviruses, MCPyV consists of a circular, doublstraded DNA 
genome of about 5.3kb that is packaged into virions comprised of VP1 and VP2 capsid 
proteins.  The genome is bisected into an early region and a late region by a central non-
coding control region (NCCR) which contains the viral origin of replication (Ori) and 
promoter sequences.  The early promoter regulates the expression of the Tumor antigen 
locus; this open reading frame is multiply spliced into various gene products, including 
LT, sT, 57kT, and ALTO.  The late promoter controls the expression of the viral capsid 
proteins, VP1 and VP2 (23).   
  
 The polyomavirus LT protein is a highly multifunctional protein that both 
manipulates the host cell cycle and initiates replication of the viral genome.  The N-
terminal region of LT contains conserved binding sites for various cellular proteins, 
including DnaJ heatshock protein family members and pRb, which serve to drive the host 
cell into a proliferative state.  The C-terminal half of the protein contains functional 
domains required for initiating the replication of the viral genome, including a viral origin 
binding domain (OBD) that allows LT to bind directly to the Ori within the viral NCCR, 
and a helicase domain which is required for unwinding of the viral DNA (8,23).  In 
SV40, LT also plays a major role in regulating both the early and late promoters (140-
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148).  The early promoter is activated by a variety of cellular transcription factors, 
including Sp1, Sp2, and NFAT, which drive initial activation of the T-antigen locus (84-
86).  As SV40 LT protein accumulates, it silences the early promoter and begins initiating 
replication of the viral genome.  After replication, the accumulated LT is then able to 
efficiently stimulate the late promoter, which drives expression of the viral capsid 
proteins (87,149,150).  Whether MCPyV LT can similarly regulate either the early or late 
viral promoters has not yet been investigated.   
  
 MCPyV sT has been shown to play an important role in both viral replication and 
MCPyV associated cancers.  MCPyV sT stabilizes LT expression and enhances LT-
mediated replication of the viral DNA (10,40).  Additionally, sT uses it’s C-terminal 
PP2A binding domain to manipulate the host cell in a variety of ways to induce cellular 
proliferation and transformation.  Some of these functions include instigating 
hyperphosphorylation of 4E-BP1 which consequently induces high levels of cap-
dependent translation (27).  MCPyV sT can also transform primary rat cells, and has been 
repeatedly shown to be necessary for maintaining the transformed phenotype of many 
MCPyV-associated MCC tumors (27,33,34).  Interestingly, sT has been shown to inhibit 
NF-κB signaling through its association with certain PP2A subunits and the NEMO 
adaptor protein (38).  No report has thus far demonstrated a role for sT in regulating 
either of the viral promoters.  In SV40 polyomavirus, sT plays a much less prominent 
role in both cellular transformation and the normal viral life cycle.  Additionally, it does 
not regulate either of the two viral promoters, although one report showed that SV40 sT 
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expression could complement a low-level of LT expression to activate the Late promoter 
in a cooperative fashion (89).   
  
 We sought to better understand how the viral promoters are regulated by both LT 
and sT during MCPyV infection.  Using a luciferase reporter, we investigated the 
potential role(s) of both MCPyV LT and sT in the regulation of both the native MCPyV 
NCCR as well as the early and late promoters in isolation.  Our results exhibit a 
surprising departure from what has been known for SV40 promoter regulation.  While 
replication does seem to play a critical role in triggering the activation of the late 
promoter, LT requires sT co-expression to robustly activate the late promoter in the 
context of the native NCCR.  Interestingly, reducing the binding affinity of LT for the 
viral Ori, through mutation of either the viral Ori sequence itself or with LT 
phosphomutants described in Chapter 2, diminishes LT’s ability to stimulate the late 
promoter, even in the context of sT co-expression.  Surprisingly, LT showed an inhibitory 
effect on the late promoter when this sequence is isolated from the rest of the NCCR, 
even in the context of sT co-expression.  These results highlight the importance of the Ori 
sequence for directing LT to the viral DNA, providing yet another example of MCPyV 
sT’s more prominent role in the viral life cycle as compared to those of other 
polyomaviruses studied thus far.   
  
4.3 RESULTS 
4.3.1 The MCPyV Late Promoter is Activated by Coexpression of Both LT and sT in the 
Context of an Intact NCCR 
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 Our previous studies of phosphorylation modification of MCPyV LT identified 
four sites: T271, T297, T299, and S816 (see Chapters 2 and 3).  Of those four sites, the 
functional relevance of T271 has not yet been established, despite being identified with 
high confidence (see Figure 2.1).  An important viral process not yet tested with the 
T271A LT mutant was regulation of MCPyV transcription, an activity which in SV40 is 
largely dependent on LT expression.  To this end, reporter constructs were generated by 
fusing the NCCR of MCPyV to a luciferase reporter plasmid such that luciferase 
expression would be driven by either the Early or Late promoter regions (see Figure 4.1).  
These two reporter constructs (NCCR Early and NCCR Late) were then co-expressed 
with MCPyV LT and sT.  LT expression had little effect on the early promoter, but had a 
robust activating effect on the late promoter only in the context of sT coexpression 
(Figure 4.2A and data not shown).  The T271A mutant behaved identically to wild-type 
LT in all cases, precluding further study of this mutant (data not shown).  Interestingly, 
sT expression alone was able to moderately but reproducibly activate both the early and 
late constructs approximately two-fold at all time points tested with the most robust 
activation seen on the late promoter when LT and sT were co-expressed (Figure 4.2A and 
data not shown). 
  
 To rule out whether LT and/or sT could act as a global activator of transcription, 
we tested whether these proteins could affect an interferon-sensitive response element 
(ISRE).  MCPyV proteins were co-transfected with a luciferase reporter under the control 
of an ISRE.  Cells were then treated with or without recombinant IFN-α.  Luciferase 
activity was greatly stimulated by IFN treatment as would be expected.  Expression of the 
	   93	  
MCPyV proteins did not activate this protein in the absence of IFN.  Interestingly, 
expression of LT and especially sT severely attenuated the activation induced by IFN 
treatment, showing that these proteins can actually repress this promoter (Figure 4.2B).  
This finding is supported by a study showing that MCPyV sT can negatively regulate NF-
κB signaling (38).  These results established that the activation of the viral promoters was 
due to a specific interaction with MCPyV LT and sT, and not due to a more global 
activation of cellular transcription.  
  
4.3.2 Increased LT Expression Alone Does Not Account for Activation of the Late 
Promoter 
 The observation that MCPyV LT required sT co-expression to activate the NCCR 
Late reporter was surprising to us (Figure 4.2A); in SV40, LT is able to activate the late 
promoter by itself following replication (87,148-150).  To our knowledge, there is only 
one report showing that SV40 sT could complement LT activation of the late promoter, 
but only in situations where LT expression was “sub-optimal” (89).  It has been well 
established by our lab and others that sT expression can stabilize LT expression (data not 
shown and (10,40)).  We therefore asked whether LT’s robust activation of the late 
promoter when sT was co-expressed was due to an increase in LT stabilization mediated 
by sT. Cells were transfected with the NCCR Late reporter construct and an increasing 
amount of LT expression construct either alone or with sT co-expression.  Lysates were 
immunoblotted for LT and sT expression to assess the extent of LT stabilization (Figure 
4.3). 
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 Interestingly, LT was able to robustly activate the late promoter at any given 
expression level, but only in the context of sT co-expression (Figure 4.3A).  Western blot 
analysis showed that co-expression of sT did in fact stabilize LT expression (Figure 4.3B, 
compare LT expression of a given level when sT is absent or present).  The expression 
level of LT alone, however, did not explain the activation of the late promoter.  For 
example, the overall LT expression level was similar between the 2xLT/sT and 5xLT 
samples; however, the late promoter was only robustly activated in the 2XLT/sT 
condition (Figure 4.3B).  Furthermore, the LT expression level of 5xLT is well above that 
seen for 1xLT/sT, yet it is only in the latter condition that the late promoter is robustly 
activated (Figure 4.3B).  These observations indicate that sT expression has enhancing 
activity on the late promoter independent of its ability to stabilize LT expression.  It is 
important to note that this activation phenotype was somewhat reduced in the 5xLT/sT 
setting; it is possible that LT might saturate whatever helper function sT might have when 
expressed at this level, although additional experiments will have to be performed to 
more clearly define this phenomenon.   
 
4.3.3 Replication of the NCCR Reporter Partially Contributes to Late Promoter 
Activation 
 Polyomaviruses commonly exhibit robust late promoter activation following 
replication.  The NCCR reporter constructs used in this study retain an intact Ori which 
would presumably be targeted by LT for replication.  In addition to MCPyV LT and sT 
acting as molecular switches for late promoter activation, increasing numbers of reporter 
plasmid could artificially inflate the reporter signal due to an increase in reporter copy 
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number.  Additionally, sT’s stabilization of LT is known to stimulate LT’s ability to 
replicate the viral Ori (10).  The results in Figures 4.2 and 4.3 could therefore be solely 
due to an increase in copy number of the NCCR reporter.  
  
 To begin addressing this question, we introduced the previously reported Ori350 
mutation into the NCCR reporter construct (10,49,151).  This mutation was derived from 
an MCC tumor and introduces a single nucleotide substitution in pentanucleotide 7 of the 
MCPyV Ori (Figure 4.1), which severely abrogates LT-mediated replication from this 
Ori (10).  We then used quantitative PCR to measure the amount of either wild-type or 
Ori350 mutated NCCR reporter plasmids in the presence and absence of MCPyV LT and 
sT after four days of expression (Figure 4.4A).   
  
 As expected, the wild-type NCCR Late reporter replicated to a high degree (about 
two-fold) in the presence of both LT and sT; expression of just LT induced a modest 
increase in reporter number.  The Ori350 NCCR Late reporter also replicated to a small 
degree when LT and sT were co-expressed, but this replication was severely abrogated 
compared to the wild-type NCCR Late reporter (Figure 4.4A).  Interestingly, examination 
of luciferase activity in this setting shows that copy number only partially contributes to 
the observed increase in luciferase activity driven by the NCCR Late reporter (Figure 
4.4B).  The luciferase activity of the WT NCCR Late reporter was stimulated 
approximately eight-fold when LT and sT were co-expressed (Figure 4.4B), even though 
the total copy number only increased two-fold in this setting (Figure 4.4A).  Additionally, 
even though the Ori350 NCCR Late reporter did replicate to a small but measurable 
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degree when LT and sT were co-expressed, this construct failed to exhibit luciferase 
activity over vector control.  A previous report showed by ChIP analysis that LT binding 
to Ori350 is greatly reduced, presumably because this mutation disrupts a key LT binding 
site (10).  It is possible, therefore, that LT binding to the Ori is required for its ability to 
activate the late promoter.  These data suggest that the combined effect of LT binding to 
the viral NCCR and sT expression, rather than NCCR plasmid copy number alone, 
contribute to the observed increase in NCCR Late luciferase activity.           
 
4.3.4 A Phosphomutant LT With a Defective Replication Phenotype Still Robustly 
Activates the Late Promoter 
 In a previous chapter, I described two LT phosphomutants (T297A and T299A) 
which exhibited altered replication phenotypes (see Chapter 2).  The T297A mutant 
exhibits enhanced replication of MCPyV Ori plasmids, likely because it can bind the Ori 
with greater affinity than wild-type LT; conversely, the T299A mutant, which exhits 
reduced binding to the viral Ori, fails to replicate MCPyV Ori plasmids (Figures 2.3, 2.5 
and 2.6).  To further probe whether replication plays a role in activating the late 
promoter, I tested these mutants for their ability to stimulate NCCR Late promoter driven 
luciferase activity in the presence or absence of sT (Figure 4.5). Southern blot analysis 
confirmed that the T297A mutant could replicate to a high degree, and that this activity 
was greatly stimulated by co-expression of sT; T299A on the other hand failed to 
replicate plasmids with or without sT co-expression (data not shown).  Surprisingly, all 
LT mutants behaved similarly to wild-type LT: they were all able to activate the NCCR 
Late reporter, but only when co-expressed with sT.  Interestingly, the activation of the 
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NCCR Late reporter was slightly attenuated with the T299A mutant, which has reduced 
binding affinity to the MCPyV Ori (Figure 2.6).  This is in agreement with the Ori350 
NCCR Late promoter reporter data presented in Figure 4.4, where reduced MCPyV LT 
binding to the NCCR Late promoter reporter prevented activation of the promoter despite 
a small level of observed replication (see section 4.3.3).  Together, these results rules out 
replication of these plasmids as a major contributing factor for the increased luciferase 
activity, and suggest that LT binding to the Ori in the presence of sT expression is critical 
for NCCR Late reporter activation.   
 
4.3.5 MCPyV LT Silences the Late Promoter in the Absence of Ori Sequences 
 The experiments presented thus far have been in the context of a native NCCR, 
which includes both promoter sequences and the viral Ori.  Data presented in Figures 4.4 
and 4.5 suggest that binding of the Ori sequences and/or replication in the presence of sT 
may play a major role in LT’s ability to activate the late promoter.  We asked how LT 
and sT might act on the Late promoter when the Ori was no longer present.  The isolated 
Late promoter (highlighted in green in Figure 4.1) was cloned into the same luciferase 
reporter vector and assessed for activation by LT and sT.  sT was still able to activate the 
isolated Late reporter when expressed alone; however, LT expression actually reduced 
activation of the isolated Late reporter below vector control levels.  Co-expression of sT 
and LT showed activity similar to vector (figure 4.6A).  We were surprised to see LT 
show such a robust silencing effect; we therefore tested whether scaling down the dose of 
LT would relieve this repression.  Interestingly, LT showed a robust silencing effect at all 
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doses tested; expression of sT was not able to overcome this silencing effect, although it 
still activated the late promoter when expressed alone (data not shown).              
 
4.4 DISCUSSION 
 Thus far, little research has been done to understand how MCPyV gene 
expression is regulated. Knowledge of viral gene regulation is important not just for 
understanding natural infection, but also in the case of MCPyV associated cancers, where 
high expression of the viral oncogenes is necessary for tumorigenesis.  This work 
represents a preliminary investigation of the regulation of the MCPyV promoters through 
the lens of the viral protein products themselves.  Polyomaviruses generally utilize the LT 
protein as a major regulator of both early and late gene transcription (87,148-150).  
MCPyV sT has also shown itself to be a critical protein involved in various MCPyV 
activities (10,27,34,38,40), so both of these proteins were tested for their ability to 
regulate the early and late viral promoters.   
 
 Reporter constructs were first generated utilizing the entire NCCR of MCPyV to 
keep the early and late promoters close to their native configurations (Figure 4.1).  An 
initial look at promoter activation by both LT and sT showed that sT could surprisingly 
activate both promoters at a small but reproducible level (two-fold, Figure 4.2A and data 
not shown).  This was independent of time-point or promoter (data not shown).  
Interestingly, expression of LT alone showed little activity, in some cases even repressing 
the late promoter (Figure 4.2A, Day 3).  At four days post transfection, however, LT was 
able to robustly activate the late promoter, but only in the context of sT co-expression.  
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This is in contrast to SV40 where LT expression alone is able to stimulate late gene 
expression.   
 
 The stimulation of the viral promoters was not due to a global effect on 
transcription: analysis of an interferon-sensitive response element showed that LT and 
especially sT actually repressed transcription from these reporters upon interferon 
stimulation (Figure 4.2B).  sT’s cooperative activity with LT to activate the late promoter 
could partially be explained by a dramatically increased level of LT expression when sT 
is coexpressed, as sT is able to stabilize LT protein expression (40); however, higher LT 
expression alone was not able to stimulate the NCCR Late promoter (Figure 4.3).  Even 
with a five-fold increase in transfected LT, sT was required for robust activation of the 
NCCR Late promoter (Figure 4.3).       
 
 The observed increase in the NCCR Late reporter luciferase activity could also be 
explained by the replication of this reporter in the context of LT expression.  These 
reporter constructs contain the native MCPyV NCCR, which includes the viral Ori.  LT 
binds to the viral Ori to initiate replication (See Chapter 2) and could presumably 
replicate these reporter constructs as well; the observed increase in the NCCR Late 
reporter luciferase activity could be due to an increase in reporter copy number after four 
days of LT expression.  To address this issue, we measured the copy number of NCCR 
plasmids in cells after four days with or without LT or sT expression.  While a two-fold 
increase in plasmid number was evident when LT and sT were co-expressed, the increase 
in NCCR Late promoter activation (> 8 fold) far exceeded this increase in plasmid count 
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(Figure 4.4).  We also examined an NCCR with a point mutation in a LT binding site 
located in the viral Ori (termed Ori350, Figure 4.1), which has previously been shown to 
have reduced replication and LT binding (10,49).  This mutant NCCR was still able to 
replicate to a very small degree when LT and sT were co-expressed, but the NCCR Late 
promoter failed to be activated from this construct (Figure 4.4).  Additionally, expression 
of phosphomutant LT proteins which either exhibit enhanced (T297A) or abrogated 
(T299A) replication were still able to activate the NCCR Late promoter, again only in the 
context of sT co-expression (Figure 4.5).  These results indicate that the promoter 
activation phenomenon is not likely due solely to an increase in reporter copy number.   
  
 Interestingly, when the Ori and Early promoter are removed, LT appears to 
suppress the isolated late promoter, even when sT is co-expressed (Figure 4.6).  A similar 
phenomenon can be noted in the NCCR construct at day 3 (Figure 4.2, Day 3 data).  This 
isolated Late promoter construct represents an artificial setting that demonstrates what 
might happen at this promoter prior to replication.  In the greater scheme of the viral life 
cycle, it makes sense for the late promoter to be repressed prior to genome amplification. 
  
 Polyomaviruses have traditionally used replication as a major switch towards 
activating the late promoter.  The data presented here supports the notion that the viral 
Ori is critical for efficient activation of the late promoter.  Both an NCCR mutated with 
the Ori350 LT binding site mutation and a LT mutant with decreased affinity for the viral 
Ori (T299A, see Figure 2.6) showed attenuated activation of the late promoter, albeit to 
different degrees.  Removal of the Ori revealed LT’s ability to strongly repress the late 
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promoter (Figure 4.6).  These data suggest that LT binding to the Ori is required for 
efficient activation of the late promoter.  The molecular mechanisms by which Ori 
binding stimulates Late promoter activation, and only in the context of sT co-expression, 
are not clear.  It is possible that replication of the viral genome causes physical changes 
to the viral chromatin structure that allow access to cellular transcription factors.  
MCPyV LT is known to recruit the host cellular chromatin factor Brd4 to viral replication 
foci; it is possible that Brd4 not only recruits RFC1 to help stimulate replication, but also 
occupies newly formed viral genomes to then recruit P-TEFb and stimulate transcription 
(50).  Additionally, other factors left over after replication, such as PCNA, may signal or 
recruit transcription factors, or interact with LT or sT in some way as to stimulate late 
promoter activation.  All of these factors represent exciting areas of research that should 
be pursued to increase our understanding of the activation of late gene expression and 
virion assembly.  Finally, it is interesting to note that sT was only able to co-activate the 
late promoter in the context of an intact NCCR: although sT alone was able to activate 
the Isolated Late reporter modestly, it was unable to counteract LT’s repressive activity 
(Figure 4.6).  This may indicate that sT activity is somehow tied to LT binding to the Ori, 
although the molecular mechanisms of this interaction remain largely speculative at this 
point.      
  
 The studies presented in this chapter focus exclusively on the regulation of the 
late promoter. The early promoter was similarly studied, both in the context of the native 
NCCR, as well as in isolation.  Results from these experiments were much more variable 
and inconsistent, although in general sT expression was able to stimulate both the early 
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and late promoters at almost all time points (data not shown).  This stimulation was 
consistently modest (two-fold) but extremely reproducible.  It is likely that sT exhibits 
some activity that somehow primes the host cell for transcription from the viral genome, 
likely through its PP2A binding activity.  It would be interesting to test whether PP2A 
binding mutants show differential activity on either promoter, or on sT’s ability to co-
activate the late promoter with LT.   
  
 Ultimately, without a robust infection system, the data presented here represent a 
somewhat artificial look at MCPyV transcription; a true infection system with a natural 
host cell will greatly advance our understanding of MCPyV virology.  It would similarly 
be interesting to examine the MCPyV gene expression dynamics of both the early and 
late promoters in the context of Merkel cell infection, as this may provide clues towards 
understanding the early events of oncogenesis.  Unfortunately, cells lines of either human 
Merkel cells or even MCPyV-negative MCC cells do not currently exist, further 
hampering progress towards better understanding this important tumor virus.   
 
 Even with these limitations, however, this preliminary study sheds some light on 
MCPyV late promoter activation, and once again highlights how MCPyV is distinct from 
other polyomaviruses.  Whereas SV40 LT is largely sufficient on its own to regulate viral 
gene expression and transform infected cells, MCPyV has shown a greater dependence 
on sT function for both tumorigenesis and, in this study, promoter activation.  Ultimately, 
a better understanding of viral gene expression, both in the context of natural infection 
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and in Merkel cells, will help advance our understanding of MCPyV pathogenesis and 
cancer progression.        
      
4.5 FIGURES 
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FIGURE 4.1   
 
 
FIGURE 4.1:  The MCPyV Non-coding Regulatory Region.  The regulatory region of 
the MCPyV R17b isolate was used to generate the NCCR Early and NCCR Late 
reporters.  Perfect LT binding sites (GAGGC pentanucleotides) are highlighted in red, 
while inverted complementary sequences (CTCCG) are highlighted in blue.  Imperfect 
repeats are noted in orange and light blue.  The Ori350 mutant is a CA substitution in 
pentanucleotide 7 which abrogates replication (asterisk, (10)). The location of the early 
and late regions of MCPyV are noted.  The isolated Late Promoter used in this study is 
highlighted in green.    
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FIGURE 4.2 
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FIGURE 4.2:  MCPyV LT and sT cooperate within the NCCR to activate the late 
promoter.  (A) 293 cells were co-transfected with NCCR Late Luciferase Reporter and 
various combinations of MCPyV LT and sT expression constructs.  Cells were collected 
at the indicated times post transfection.  Luciferase activity was normalized to protein 
content.  Graphs show the mean of a triplicate transfection; error bars represent the 
standard deviation from the mean.  Data are representative of three independent 
experiments.  (B) 293 cells were co-transfected with an Interferon-Sensitive Response 
Element reporter plasmid and the indicated MCPyV gene construct.  Twenty-four hours 
post-transfection, cells were stimulated with recombinant IFN-α or PBS.  Forty-eight 
hours post-transfection, cells were collected.  Luciferase activity was normalized to 
protein content. Graphs show the mean of a triplicate transfection; error bars represent the 
standard deviation from the mean.  Data are representative of three independent 
experiments.  
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FIGURE 4.3 
 
 
FIGURE 4.3: LT protein level alone does not explain late promoter activation. 293 
cells were co-transfected with the NCCR Late Luciferase reporter and increasing 
amounts of LT expression plasmid with or without a constant amount of sT expression 
plasmid.  Cells were collected four days post-transfection.  (A)  Luciferase activity was 
normalized to protein content. Graphs show the mean of a triplicate transfection; error 
bars represent the standard deviation from the mean.  (B) Lysates were separated by 
SDS-PAGE and immunoblotted for the indicated proteins.  Data are representative of 
three independent experiments.  
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FIGURE 4.4 
FIGURE 4.4: An intact origin of replication is required for late promoter activation.  
(A) 293 cells were transfected with the indicated MCPyV proteins and either WT NCCR 
Late or the replication-defective Ori350 NCCR Late Luciferase reporter.  Whole-
genomic DNA was extracted from cells collected four days post-transfection.  NCCR 
plasmids were measured by qPCR (calculated against a standard curve, depicted on the 
right, with an R2 value of 0.99988) and normalized to GAPDH.  (B) 293 cells were 
transfected as in (A) and collected four days-post transfection.  Luciferase activity was 
normalized against protein content. Graphs show the mean of a triplicate transfection; 
error bars represent the standard deviation from the mean.  Data are representative of 
three independent experiments.  
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FIGURE 4.5 
 
 
FIGURE 4.5: A MCPyV LT replication-defective mutant can still activate the late 
promoter. 293 cells were co-transfected with the NCCR Late Luciferase reporter and the 
indicated LT expression plasmid with or without sT expression plasmid.  Cells were 
collected four days post-transfection.  (A)  Luciferase activity was normalized protein 
content. Graphs show the mean of a triplicate transfection; error bars represent the 
standard deviation from the mean.  (B) Lysates were separated by SDS-PAGE and 
immunoblotted for the indicated proteins.  Data are representative of three independent 
experiments.  
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FIGURE 4.6 
   
FIGURE 4.6: MCPyV LT represses the late promoter when the viral origin is 
absent. 293 cells were transfected with the MCPyV isolated Late Luciferase reporter 
with or without sT co-expression.  Two-days post-transfection, cells were collected, and 
luciferase activity was normalized to protein concentration. Graphs show the mean of a 
triplicate transfection; error bars represent the standard deviation from the mean. Data are 
representative of four independent experiments.  
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
5.1: Regulation of MCPyV LT Function by Phosphorylation 
5.1.1: Regulation of Protein Function by Phosphorylation 
 A majority of my thesis work has centered around a fundamental question: how 
are the myriad of functions of a complex viral protein like MCPyV LT regulated to allow 
for the exquisitely coordinated progression of viral infection?  The LT protein of 
polyomaviruses is involved in almost every facet of the viral life cycle, including 
manipulating the host cell cycle to favor proliferation, initiating replication of the viral 
genome, and (usually) controlling the expression of early and late genes such that T-
antigens are expressed first to manipulate the cell, and capsid proteins are expressed only 
when it is convenient to produce new virions.  Understanding how LT protein function is 
regulated is the heart of elucidating how polyomaviruses coordinate their life cycle in 
host cells.   
  
 Polyomavirus LT proteins were readily identified as highly phosphorylated, and 
the functional relevance for many of these modifications remain a mystery even for 
SV40, arguably one of the best studied viruses in the world.  Phosphorylation is a 
versatile post-translational modification, as it is readily added and removed from 
substrates by kinases and phosphatases, respectively, allowing for a dynamic regulation 
of protein function in response to an ever changing cellular environment.  In addition to 
acting as a molecular mark whose presence or absence can be recognized by other 
proteins, the negative charge inherent to the phosphate moiety can be utilized to alter 
protein structure or interaction with other proteins.   
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 The work presented here represents a first look at how phosphorylation regulates 
MCPyV LT function, and provides many avenues of research worth pursuing to better 
understand the basic life cycle of this important tumor virus.   
 
 5.1.2: Regulation of MCPyV Replication by Phosphorylation of LT T297 and T299 
 The work presented in Chapter 2 identified three threonine phosphorylation sites 
on MCPyV LT (Figure 2.1).  Ultimately, two of them (T297 and T299) proved to be 
important regulators of LT-mediated replication.  Identification of T299 as a phospho-site 
was encouraging to me because of its homology to a well-described regulatory threonine 
in SV40 LT, providing confidence in the validity of my mass spectrometry data.  Its 
homology to T124 in SV40 LT naturally led me to ask whether this mutant abrogates 
replication; this hypothesis ultimately proved to be correct (Figures 2.3 and 2.5).  To my 
surprise, T297 was identified as being equally important, if in an opposite fashion; the 
T297A mutant actually showed enhanced replication, well over that seen for wild-type 
LT (Figures 2.3 and 2.5).  This finding was completely unexpected to me, and led me to 
generate models to better understand the underlying molecular mechanisms.   
  
 Modeling of the LT OBD suggested that T297 faces the LT/DNA interaction 
interface (Figure 2.2); electrostatic theory would predict that a phosphate moiety at this 
site would be repelled by the negatively charged phosphate backbone of DNA; therefore, 
the alanine mutant would have this repulsive interaction abrogated.  In line with this 
reasoning, electromobility shift assays showed that the T297A mutant had enhanced 
affinity for the viral Ori, while the T299A mutant showed reduced Ori binding.  To test 
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the hypothesis that electrostatic interactions drive T297’s regulation of replication, I 
could test whether a T297D or T297E mutant evidence reduced binding.  The functional 
consequence of T299 phosphorylation is not as clear.  In the homologous site on SV40 
LT, the major outcome of phosphorylation at this site is stimulation of interactions 
between adjacent hexameric LT complexes assembled at the viral origin.  Using an 
elegant series of DNA probes, Barbaro and colleagues were able to show this double-
hexamer interaction and its dependence on T124 phosphorylation in SV40 by splitting the 
SV40 Ori in half, retaining two of the four LT binding sites in both probes (73).  The 
SV40 Ori is largely symmetrical, with opposing pairs of GAGGC repeats for recruiting 
LT flanked by A/T rich or palindromic sequences (see Figure 1.2).  In contrast, the 
MCPyV Ori has an asymmetric organization, with as many as ten potential LT binding 
sites separated by a large A/T rich tract; a second A/T rich track caps the late end of the 
Ori (10,28).   Due to this unique nature of the MCPyV origin, as well as technical 
difficulties with my own hands, I was unable to recapitulate this finding in MCPyV LT, 
although I would predict that T299 phosphorylation behaves very similarly to T124 in 
SV40.  A more rigorous demonstration of this remains to be seen.       
  
 These data suggest a model where phosphorylation at T299 enhances LT-
mediated replication, presumably by stimulating hexamer-hexamer interactions, while 
T297 phosphorylation would act as a brake to prevent unscheduled genome replication by 
reducing the affinity of LT for the viral Ori.  Unfortunately it is currently impossible to 
begin probing the temporal dynamics of phosphorylation at these sites during the viral 
life cycle – we lack both the specific antibodies required for assessing phosphorylation at 
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these sites, and a relevant cell culture system that recapitulates a “natural infection.”  
Additionally, we have little clues as to the kinase(s) and potentially phosphatase(s) 
involved in adding or removing phosphates from these two critical threonines.  
Phosphorylation of T124 in SV40 LT is mediated by a cyclin dependent kinase in vitro 
(71); while this has not been definitively proven in vivo, the virus would likely want to 
initiate replication only when the host cell has transitioned into S-phase, when the DNA 
synthesis machinery has been primed.   
  
 Phosphorylation of T297 could follow a myriad of routes, depending on whether 
it functions to prevent premature initiation of replication, to put a brake on replication 
after amplification of the viral genomes, or both.  T297 lies within a region of LT which 
in SV40 is commonly found phosphorylated early in infection, albeit at serine residues; 
these phosphorylation marks similarly reduce SV40 LT’s capacity to replicate the viral 
genome (77,79,93).  Interestingly, it is believed that PP2A phosphatases might be 
involved in removing these marks as infection transitions to amplification of the viral 
genome (76,78).  Given sT’s ability to interact with PP2A proteins, it is interesting to 
speculate whether an additional layer of regulation of LT phosphorylation exists with this 
accessory protein.  Thus far, MCPyV sT has proven to be a major player in the MCPyV 
life cycle, quite contrary to SV40 in which it plays a largely supporting role; it would not 
be surprising, therefore, to discover that sT plays a major role in regulating LT-mediated 
transcription not just by stabilizing the LT protein but also by regulating the 
dephosphorylation of key inhibitory phosphates, like T297 phosphorylation.           
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5.1.3: Phosphorylation of MCPyV LT by ATM Kinase at S816 
 The interaction between DNA viruses and the host DDR has been an emerging 
field of interest in the past decade.  That DNA viruses must contend with the DDR 
machinery – either to subvert unwanted activities or co-opt these pathways for their own 
replication – has now become a major theme in DNA virology.  In the case of MCPyV, 
our lab showed that LT expression alone induces activation of a host DDR response (14).  
Our more recent work demonstrated that components of the DDR machinery are actively 
recruited to viral replication centers, and disruption of this machinery had a negative 
impact on viral replication (49).  It is clear that MCPyV interacts with the host DDR, but 
precisely how, and for what reason, has remained an open question.   
  
 Our identification of a cross-reactive activity with an antibody specific for serine 
345 phosphorylation of a key DDR protein, Chk1, leading to the discovery yet another 
phosphorylation site on LT: serine 816.  We immediately hypothesized that some DDR 
kinase might be responsible for this phosphorylation, as the epitope recognized by the 
cross-reactive antibody represented a classic “S/T-Q” site recognized by both ATM and 
ATR kinases, and we already knew that the DDR machinery was activated by LT and 
recruited to viral replication centers, as already outline above.  Using in vitro techniques, 
we were able to show that, indeed, ATM kinase is able to interact with LT and mediate 
phosphorylation at S816 (Figure 3.2, 3.3 and 3.4).  We then attempted to uncover the 
functional relevance of MCPyV LT phosphorylation at S816.  MCPyV LT expression has 
a well-documented growth-inhibitory property that had been localized by our lab and 
others to the C-terminal half of the protein (13,14).  We therefore asked whether 
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phosphorylation at S816 was involved in this growth inhibition.  Clonogenic assays and 
screens of molecular markers of apoptosis seem to lend some support for this hypothesis, 
but the effects are modest, at best (Figure 3.5 and 3.6).  It is unclear whether other 
MCPyV LT function(s) are regulated by the phosphorylation of S816; even if its only 
function was indeed to arrest the host cell, it is not clear whether this activity is a strategy 
employed by MCPyV to maintain the cell in a pseudo-S-phase/G2 state, or if this 
represents a host anti-viral strategy to eliminate virally infected cells.  More rigorous 
exploration of other potential functions of S816 phosphorylation is necessary to better 
understand how MCPyV might subvert – or be victim to – the host DDR machinery.   
  
 It is interesting to note that 57kT retains the C-terminal 100 amino acids of LT, 
and presumably shares this phosphorylation site.  Although we currently do not have 
much information about 57kT’s function during infection, it would be interesting to test 
whether this protein is indeed phosphorylated at the same site, and whether this has a 
more obvious phenotype on this smaller tumor antigen.       
 
5.1.4: Uncovering the Function of MCPyV LT T271 Phosphorylation 
 One of the more fascinating aspects of MCPyV LT is the presence of a 200 amino 
acid stretch flanking the “LXCXE” pRb binding site, which is unique to MCPyV LT and 
does not exist in any other polyomavirus LT discovered thus far.  This region has been 
termed the MUR and has generated a lot of curiosity and interest, although currently no 
functional data have surfaced apart from one report showing a vacuolar sorting protein 
binds LT in this region (24).  MCPyV has thus far proven to behave very differently from 
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its more well studied SV40 counterpart, and it has been thought that understanding the 
function of the MUR may help us better understand what unique functions MCPyV LT 
has acquired.   
  
 Of particular interest to me was the identification of T271 phosphorylation.  Of 
the three sites identified in Chapter 2, the phosphorylated T271 peptide was most 
frequently captured in both the standard and titanium oxide purification schemes, 
providing high confidence that this site is likely phosphorylated during LT expression 
(Figure 2.1).  Despite this, I have been unable to find any functional phenotype for a 
T271A mutant in relation to transcription, replication, or cell cycle control.  Of all the 
work presented here, this phosphorylation site remains a major area of potential new 
research and represents a key clue into uncovering novel functions acquired by the 
MCPyV LT unique region.  It is again interesting to note that 57kT retains the amino acid 
sequence for this phosphorylation site, and therefore it may be more relevant in that 
protein than in full length LT.   
 
5.2: Regulation of Viral Transcription  
 I began my work on viral transcription primarily as a means of screening the 
T271A LT mutant for a potential phenotype.  To my surprise, contrary to what had been 
reported for SV40, MCPyV LT was unable to activate the late promoter on its own in the 
context of the native NCCR; it required sT co-expression (Figure 4.2).  I also uncovered a 
dependence on viral replication and/or binding of LT to the MCPyV Ori for robust 
activation of the late promoter (Figure 4.4 and 4.5), although this phenomenon has 
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already been described for polyomaviruses (146,147).  Unfortunately, difficulty in getting 
consistent results with the early promoter constructs, coupled with the fact that MCPyV 
LT can negatively regulate a number of control reporter constructs used in various 
reporter assays, has made progress in studying transcription preliminary at best.  
Developing a more robust transcription assay system with better transfection controls will 
help solidify the data I have already generated and hopefully lead to new discoveries with 
the early promoter as well.   
  
 A better understanding of the regulation of the early and late promoter is critical 
for advancing our knowledge of both MCPyV natural infection and its associated 
oncogenesis.  Our current lack of a viable cell-culture model for propagating virus is due, 
in part, to a lack of a tissue culture system for stimulation of the early and late promoters.  
A greater understanding of the requirements for efficient activation of these promoters 
can help us identify a more natural host cell, or engineer new tools to make propagation 
and infection with virions much less laborious.  Additionally, understanding how the 
early promoter in particular is regulated will be key for understanding how this regulation 
is altered in MCC, in which sT and LT can both be expressed and are often required for 
maintaining the cancer phenotype (9,33,34).   
 
5.3: Current Obstacles in Basic MCPyV Research 
 The major obstacle, by far, facing the field is the lack of a viable cell culture 
system for propagating virus.  Any research into the basic life cycle of MCPyV thus far 
has largely been done using overexpression of viral proteins in isolation or sometimes in 
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combination.  Re-ligated genomes or molecular clones of MCPyV have offered more 
relevant systems for exploring viral infection, but the delivery systems for these genomes 
are still artificial.  Once a viable cell culture model has been established, much of the 
work that has been performed to understand MCPyV replication, transcription, and cell 
cycle manipulation will have to be repeated.  A viable and physiologically relevant 
system might also allow us to finally uncover the function of a variety of unique aspects 
of MCPyV that have thus far eluded us, such as the function of the MCPyV LT MUR or 
the contribution of 57kT. 
     
5.4: Concluding Remarks 
 My thesis work has explored basic aspects of early MCPyV activities, focusing on 
the LT protein.  In addition to tying key post-translational modifications of LT to its 
various functions in cells, my work also highlights how MCPyV is unique among 
polyomaviruses in its greater dependence on sT; further exploration of how the 
phosphorylation sites I identified are regulated will likely uncover even more unique 
ways in which MCPyV has adapted to its host.  The eventual development of a viable and 
physiologically relevant cell culture system will pave the wave to an explosion of new 
knowledge for this critically important human tumor virus.   
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CHAPTER 6: MATERIALS AND METHODS 
 
6.1: Cell Lines, Cell Culture and Transfection 
 HEK 293, HEK 293T, HeLa and C33A cell lines were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM; Invitrogen) supplemented with 10% fetal bovine 
serum (Hyclone). HEK 293TT cells, a gift from Chris Buck (NCI), were generated by 
stably transfecting 293T cells with an SV40 LT expression plasmid, pTIH, which also 
contains a Hygromycin resistance cassette (152).  293TT cells were maintained in 
DMEM supplemented with 10% fetal bovine serum and 250 µg/mL Hygromycin B 
(Clontech).  U2OS cells were maintained in McCoy’s 5A medium (Invitrogen) 
containing 10% fetal bovine serum (Hyclone, Logan, UT, USA). FuGENE6 transfection 
reagent (Roche Applied Science), or Lipofectamine 2000 (Invitrogen) reagents were used 
to transfect 293TT, U2OS, C33A, or HeLa cells per the manufacturer’s instructions in the 
work presented in Chapter 3.  HEK 293, 293T and C33A cells were transfected using the 
calcium phosphate method as described previously (50). 
 
6.2: Recombinant Plasmids 
 Construction of the pcDNA4c-MCPyV LT, pcDNA-MCPyV LT 1-211, 
pcDNA4C-MCPyV LT 212-440, pcDNA4C-MCPyV LT 1-440, pcDNA4C-MCPyV LT 
212-817, pcDNA4C-MCPyV LT 1-817, pEGFPC1-MCPyV LT 1-440, pEGFPC1-
MCPyV LT 441-817, pEGFPC1-MCPyV LT 1-817, pcDNA4C-IIT-MCPyV LT 1-817, 
pLPCX-Cherry-LacI, pLPCX-MCPyV LT 1-817, pGEX-MCPyV LT and pcDNA4c-
MCPyV Ori plasmids have been described previously (14,50). For the phospho-mutant 
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constructs T271A, T297A and T299A, Quik-Change Site-Directed Mutagenesis 
(Stratagene) was performed.  Briefly, synthetic oligonucleotides containing the desired 
mutation were annealed with denatured template plasmid pcDNA4c-MCPyV LT and 
extended with Pfu Turbo polymerase (Agilent Technologies) following the 
manufacturer’s instructions. Unmutated plasmid DNA templates were removed by DpnI 
digestion, and the remaining DNA was used to transform DH5α competent cells. To 
generate IIT affinity-tagged constructs, a DNA sequence encoding two IgG binding 
domains of Staphylococcus aureus protein A and a TEV protease cleavage site was fused 
in frame to the N terminus of MCPyV LT constructs using the KpnI site of the 
pcDNA4c-MCPyV LT expression construct.  
  
 The NCCR reporter constructs were generated by PCR amplifying the NCCR of 
the pMoHF construct (derived from the MCPyV R17b isolate, a gift from Chris Buck, 
NCI) and subcloning into the KpnI site of pGL4-Basic (Promega).  The primers used 
were (MCPyV NCCR 1: 5’ – CGGGGTACCTGAAAAATAAATAAGG – 3’; MCPyV 
NCCR 2: 5’ – CGGGGTACCTTGTCTATATGCAGAAG – 3’).  The NCCR Ori350 
constructs were generated by introducing the CA mutation in pentanucleotide 7 of the 
MCPyV Ori sequence of pGL4-NCCR constructs using QuikChange Site-Directed 
mutagenesis (Stratagene).  The Isolated Late Reporter was generated by PCR amplifying 
the late promoter of pMoHF and cloning it into the KpnI and XhoI sites of pGL4-Basic.  
The primers used were Isolated Late For: 5’ – TAGGTACCAGGCAGCCAAGTTGTGG 
– 3’ and Isolated Late Rev: 5’ – TACTCGAGTGAAAAATAAATAAGG – 3’.   
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 The pELU-ISRE reporter plasmid for assessing Type 1 Interferon signaling was a 
gift from Dr. Susan Weiss, University of Pennsylvania.  The pTIH construct expressing 
SV40 LT, as well as the expression constructs for MCPyV sT, pMono-Blast, pWM, 
pMtBs and pMtW, were gifts from Chris Buck, NCI. All constructs were confirmed by 
DNA sequencing. 
 
6.3: Antibodies and Chemicals 
 The following antibodies were used for immunoflourescent staining: mouse anti-
Xpress (R910-25, Invitrogen), rabbit anti-RFC1 (H-300, Santa Cruz), rabbit anti-RPA70 
(2267, Cell Signaling), Alexa Fluor 594 goat anti-rabbit IgG (A11012, Invitrogen), and 
Alexa Fluor 488 goat anti-mouse IgG (A11001, Invitrogen). The polyclonal rabbit anti-
Brd4CA recognizes aa 1313–1362 (83).  The rabbit polyclonal antiserum raised against 
MCPyV VP1 was a gift from Chris Buck, NCI (17).    
  
 Antibodies used for western blotting include: mouse anti-MCPyV LT (sc-136172, 
CM2B4, Santa Cruz), mouse 2t2 (recognizes the common N-terminal domain of MCPyV 
sT and LT; gift from Chris Buck, NCI), mouse anti-glyceraldehyde 3-phosphate-
dehydrogenase (GAPDH) (G8140-01, US Biological), mouse anti-Xpress (R910-25, 
Invitrogen), rabbit anti-phosphorylated ATM Ser1981 (ab-81292, Abcam), rabbit anti-
ATM (2873s, Cell Signaling), rabbit anti-ATR (ab-2905, Abcam), mouse anti-PCNA (ab-
2426, Abcam), rabbit anti-phosphorylated Chk1 Ser345 (2348s, Cell Signaling), mouse 
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anti-actin (MAB 1501M, Chemicon), HRP conjugated goat anti-mouse (7076s, Cell 
Signaling), and HRP conjugated goat anti-rabbit (7074s, Cell Signaling). 
 
 Mouse anti-ATM (2873S, Cell Signaling), rabbit anti-ATR (ab-2905, Abcam), 
normal rabbit IgG (12-370, Millipore), and normal mouse IgG (12-371, Millipore) were 
used for immunoprecipitations. 
 
 Etoposide, wortmannin, NU 6027, caffeine and puromycin were purchased from 
Sigma.  NU 7441 was purchased from TOCRIS Bioscience.  KU 55933 was purchased 
from EMD Millipore.  AZD 7762 was purchased from Selleck Chemicals.  Calf-intestinal 
alkaline phosphatase (CIP) was purchased from New England Biolabs. Annexin V-PE 
was purchased from BioVision. AcTEV protease was obtained from Invitrogen. Western 
Lightning Plus-ECL solution was purchased from Perkin Elmer (NEL). 
  
6.4: Sample Preparation for Mass Spectrometry Analysis 
 HEK 293 cells were transfected with IIT-tagged pcDNA4c-MCPyV LT using the 
calcium phosphate method (50). Forty-eight hours post-transfection, nuclear extracts 
were prepared. Briefly, cells were resuspended in Buffer A supplemented with 
phosphatase inhibitors (10mM HEPES [pH 7.9], 10mM KCl, 0.1mM EDTA, 30mM NaF, 
1mM Na3VO4, 40mM β-glycerophosphate, 0.2 mM PMSF and protease inhibitors). Cells 
were swollen on ice for 10 min before NP-40 was added to a final concentration of 6% 
and then vortexed for 10 sec. Nuclei were pelleted by centrifugation at 1200g at 4°C for 5 
min. Nuclei were resuspended in Buffer B supplemented with phosphatase inhibitors 
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(20mM HEPES [pH 7.9], 400mM NaCl, 1mM EDTA, 30mM NaF, 1mM Na3VO4, 
40mM β-glycerophosphate, 0.2mM PMSF and protease inhibitors) and lysed by passing 
through a 22-gauge needle 10 times. Lysates were incubuated at 4°C for 1 hr and clarified 
at 20,000g at 4°C for 15 min. The supernatant was then immunopurified with IgG-
Sepharose 6 Fast Flow beads (GE Healthcare, Pittsburgh, PA, USA), pre-blocked with 
1% BSA, for 2 hr at 4°C. Bound immune complexes were washed twice with IP wash 
buffer with phosphatase inhibitors (10mM Tris-HCl [pH 8.0], 150mM NaCl, 0.1% NP-
40, 30mM NaF, 1mM Na3VO4, and 40mM β-glycerophosphate), once with IP wash 
buffer without phosphatase inhibitors, and finally once with cleavage buffer (10mM Tris-
HCl [pH 8.0], 150mM NaCl, 0.1% NP-40, 0.5mM EDTA, 0.5mM EGTA, and 1mM 
DTT). Bound proteins were then cleaved with TEV protease (Invitrogen) in cleavage 
buffer for 2 hr at room temperature.  Beads were spun down and the supernatant was 
boiled in sample buffer and resolved by SDS-PAGE. The gel was stained with Coomassie 
Brilliant blue. The band corresponding to MCPyV LT was excised and analyzed by mass 
spectrometry. 
 
6.5: Mass Spectrometry Analysis 
 The mass spectrometry analysis was provided by the Proteomics Core Facility, 
University of Pennsylvania. Protein samples were digested with trypsin as described by 
Strader et al. (153). Digested peptides were then purified by liquid chromatography using 
standard purification techniques or with a titanium oxide column (GE Healthcare 
Biosciences, Pittsburgh, PA, USA). Peptides were analyzed by nanoLC/MS/MS with a 
LTQ Mass Spectrometer (Thermo Scientific, Waltham, MA, USA) equipped with a nano 
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LC-2D HPLC system (Eksigent, Framingham, MA, USA). The data were analyzed with 
Sequest and Scaffold software. 
 
6.6: Sequence Alignment of Polyomavirus LT Proteins 
 Clone Manager 9 software was used to align the amino acid sequences of various 
polyomavirus LT proteins. Amino acid sequences were aligned using the Mult-Way view 
and BLOSUM 62 scoring matrix. Polyomavirus LT sequences and their NCBI accession 
numbers are as follows: Merkel Cell Polyomavirus LT, R17a isolate (HM011555.1); 
Murine Polyomavirus LT (NC_001515.1); African Green Monkey Polyomavirus LT 
(NC_004763.2); WU Polyomavirus LT (NC_009539.1); KI Polyomavirus LT 
(NC_009238.1); BK Polyomavirus LT (NC_001538.1); JC Polyomavirus LT 
(NC_001699.1); SV40 LT (NC_001669.1). 
 
6.7: Phyre2 Modeling of MCPyV LT Fragments 
 We modeled MCPyV LT amino acids 290–433 using Phyre2 software’s intensive 
mode (154). The PDB file was then visualized using PyMOL software (155). The model 
was oriented using the origin binding domain crystal structure reported by Harrison and 
colleagues as a reference (28). 
 
6.8: Immunoflourescent (IF) Staining 
 Cells were fixed with 3% paraformaldehyde in PBS for 20 min at 4 °C. Cells 
were incubated in blocking/permeabilization buffer (0.5% Triton X-100 and 3% BSA in 
PBS) for 10 min at room temperature and stained with specific primary antibodies (as 
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described in the figure legends) at room temperature for 60 min. After incubation, the 
cells were washed three times with blocking/permeabilization buffer and incubated with 
Alexa Fluor 594 goat anti-rabbit IgG and 488 goat anti-mouse IgG (Invitrogen, 
Molecular Probes, Ashburn, VA, USA) for an additional 60 min. After incubation with 
the secondary antibodies, cells were counterstained with DAPI (4',6'-diamidino-2-
phenylindol) and examined with an Olympus IX81 inverted fluorescence microscope. 
 
6.9: Microscopy and Image Analysis 
 All immunofluorescent images were collected using an inverted fluorescence 
microscope (Olympus IX81) connected to a high-resolution charge-coupled device 
camera (QImaging, FAST1394). Images were analyzed and presented using SlideBook 
5.0 software (Intelligent Imaging Innovations, Inc., Denver, CO, USA). The scale bars 
were added using ImageJ software. 
 
6.10: Southern Blotting 
 Replication assays were performed as described previously (49). Briefly, MCPyV 
LT constructs were transfected into C33A cells using the calcium phosphate method (50). 
Forty-eight hours post-transfection, whole genomic DNA was extracted. Genomic DNA 
(15 µg) was digested with BamHI, treated with or without DpnI at 37 °C overnight, and 
separated on a 0.7% agarose gel. DNA was transferred to a Hybond-N+ nitrocellulose 
membrane (Amersham, Piscataway, NJ, USA) and hybridized with a pcDNA4c-MCPyV 
Ori probe labeled with [α-32P] dCTP using Prime-It II random primer labeling kit 
(Agilent Technologies) per the manufacturer’s instructions. The results were analyzed 
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using a Phosphorimager (Typhoon 9400; GE Healthcare). 
 
6.11: Western Blotting 
 For the work presented in chapter 2, cells were lysed in hypertonic lysis buffer 
(10mM HEPES [pH 7.9], 500mM NaCl, 3mM MgCl2, 1mM dithiothreitol, 1mM 
phenylmethylsulfonyl fluoride, and protease inhibitors) by passage through a 22-gauge 
needle 10 times. After a 20-min incubation on ice, the soluble and insoluble fractions 
were separated by centrifugation at 5,000rpm for 10 min at 4°C. The supernatants (20 µg) 
were resolved on a SDS-PAGE gel and transferred to PVDF membrane. Membranes 
were blocked in 5% PBST-milk (5% w/v milk, 0.1% Tween in Phosphate-buffered 
Saline, [PBS]) for 1 hr at room temperature and incubated in PBST-milk containing 
primary antibodies at room temperature for 1 hr. After washing three times with PBST, 
membranes were then incubated with HRP-conjugated secondary antibodies in PBST-
milk for 1 hr at room temperature. Western blots were developed using ECL solution and 
images were captured using a Fuji imaging system. 
  
 For immunoblotting with phosphospecific antibodies in chapter 3, cells were 
collected thirty-six hours post transfection in lysis buffer (10mM HEPES [pH 7.9], 
300mM NaCl, 3mM MgCl2, 1mM DTT, 1mM PMSF, 3mM sodium butyrate, 1mM 
PMSF, 1mM NaF, 100µM Na3VO4, supplemented with protease inhibitor cocktails 
(Roche) and S/T protein phosphatase inhibitor cocktails (Sigma)) and lysed by passing 
through a 26-gauge needle 10 times. After a 20 min incubation on ice with occasional 
vortexing, the soluble and insoluble fractions were separated by centrifugation at 5,000 
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rpm for 5 min at 4°C. The supernatant (20µg) was resolved by SDS-PAGE. Phosphatase 
inhibitors (1 mM NaF and 100 µM Na3VO4) were added to electrophoresis buffer and 
transfer buffer. Membranes were blocked in 5% TBST-milk (5% w/v milk, 0.1% Tween 
in Tris-Buffered Saline [TBS]) for 1 hour at room temperature and incubated in TBST-
milk containing primary antibodies at 4°C overnight. For anti-phospho protein 
antibodies, TBST-BSA was used instead of TBST-milk. Membranes were then incubated 
with HRP conjugated secondary antibodies in TBST-milk for 1 hour at room 
temperature.  
  
 For immunoblots in Chapter 4, lysates generated for the luciferase assay using the 
Reporter Lysis system (Promega) were separated (25µL lysate) by SDS-PAGE and 
blotted with the antibodies indicated in the figure legends.   
 
 Western blots were developed using ECL solution and images were captured 
using a Fuji imaging system. 
 
6.12: Affinity Purification of MCPyV LT 
 HEK 293 cells were transfected with constructs expressing IIT-tagged MCPyV 
LT (wild-type or mutant) using the calcium phosphate method. Forty-eight hours post-
transfection, nuclear extracts were prepared. Briefly, cells were resuspended in Buffer A 
(10mM HEPES [pH 7.9], 10mM KCl, 0.1mM EDTA, 0.2mM PMSF, and protease 
inhibitors). Cells were swollen on ice for 10 min before NP-40 was added to a final 
concentration of 6% and then vortexed for 10 sec. Nuclei were pelleted by centrifugation 
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at 1200g at 4°C for 5 min. Nuclei were resuspended in Buffer B (20mM HEPE [pH 7.9], 
400mM NaCl, 20% glycerol, 1mM EDTA, 0.2mM PMSF and protease inhibitors) and 
lysed by passing through a 22-gauge needle 10 times. Lysates were clarified at 20,000g at 
4°C for 15 min. The supernatant was then immunopurified with IgG-Sepharose 6 Fast 
Flow beads (GE Healthcare) pre-blocked with 1% BSA for 2 hr at 4°C. Bound immune 
complexes were washed three times with IP 150 buffer (10mM Tris-HCl [pH 8.0], 
150mM NaCl, 0.1% NP-40) and once with TEV cleavage buffer (50mM Tris-HCl [pH 
8.0], 6% glycerol, 0.5mM EDTA, 0.5mM DTT, 1mM PMSF). Bound proteins were then 
cleaved with TEV protease (Invitrogen) in TEV cleavage buffer, overnight at 4°C. The 
beads were spun down and the supernatant collected for further biochemical analysis. 
 
6.13: Electromobility Shift Assays (EMSA) 
 The EMSA probe was generated by PCR amplifying a portion of pcDNA4c-
MCPyV Ori (Forward Primer: TTG GCA GAG GCT TGG GGC TCC, Reverse Primer: 
GCG GAA TTC TAA GCC TCT TAA GCC TC). The PCR product was purified using a 
Qiagen PCR Purification Kit (Cat# 28104) following the manufacturer’s instructions. The 
purified probe (100 ng) was then 5' labeled with [32P-γ] ATP with T4 Polynucleotide 
Kinase (New England Biolabs, Ipswich, MA, USA) following the manufacturer’s 
instructions. The labeled probe was then diluted 1:50 before being used in the EMSA. 
 
 Binding reactions (20 µL) were assembled on ice. Various amounts of affinity 
purified MCPyV LT was mixed with 40 fmol labeled probe in binding buffer (30mM 
Tris-HCl [pH 8.0], 10% glycerol, 0.5µg BSA, 10ng poly d(I-C), 40ng Sonicated Salmon 
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Sperm DNA, 5mM AMP-PNP, 1mM DTT, and 1mM PMSF). Reactions were incubated 
at room temperature for 25 min and then separated on a 4% non-denaturing 
polyacrylamide gel in 0.5 × TBE (Tris-Borate-EDTA) at 120V for 3 hr. The gel was 
dried and subjected to autoradiography. The non-hydrolyzable ATP analogue, adenylyl 
imidodiphosphate (AMP-PNP) was obtained from Sigma (St. Louis, MO, USA, Cat# 
A2647). 
 
6.14: Unwinding Assay 
 The probe was generated by annealing two oligos (80ng each) spanning the 
central portion of the MCPyV Ori sequence (Figure 2.7 A) (Top Strand Oligo: GTG ACT 
TTT TTT TTT CAA GTT GGC AGA GGC TTG GGG CTC CTA GCC TCC GAG GCC 
TCT GGA AAA AAA AGA GAG AGG CC; Bottom Strand Oligo: CAG AGG CCT 
CTC TCT TTT TTT TCC AGA GGC CTC GGA GGC TAG GAG CCC CAA GCC TCT 
GCC AAC TTG AAA AAA AAA AGT CAC). The four-nucleotide overhang was filled 
in using Klenow DNA Polymerase (New England Biolabs) by mixing the duplexed probe 
in a reaction containing 0.1mM dTTP, dGTP, and [32P-α] dCTP and incubating at room 
temperature for 20 min. After adding dATP to a final concentration of 0.1mM, reactions 
were incubated for another 20 min at room temperature. 
  
 Various amounts of purified MCPyV LT were combined with 60pg of labeled 
probe in 20µL unwinding reaction buffer (30mM HEPES [pH 8.0], 0.1mg/mL BSA, 
7mM MgCl2, 4mM ATP, 40mM creatine phosphate, 25µg/mL creatine phosphate 
kinase). Reactions were carried out at room temperature for 1 hr. Reactions were stopped 
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by adding 5µL 5×Stop Buffer (2.5% SDS, and 100mM EDTA). Loading dye 
(bromophenol blue, 4% sucrose and 1XTBE) was added and samples were separated on 
an 11% non-denaturing PAGE in 0.5XTBE. Gels were dried and analyzed using 
autoradiography. 
 
6.15: Helicase Assay 
 The helicase assay was performed as previously described with minor 
modification (14). Wild-type or mutant MCPyV LT fused to an IIT tag was expressed in 
HEK 293 cells and purified using IgG Sepharose 6 Fast Flow beads (GE Healthcare), 
which were preblocked with 1% BSA in PBS at 4 °C for >1 hr. Beads with bound LT 
were split into two equal fractions for SDS-PAGE/Coomassie brilliant blue staining and 
helicase assays, respectively. To label the helicase assay substrate, 35ng of a 31-mer 
oligo (5'-CCA GGG TTT TCC CAG TCA CGA CGT TGT AAA C-3') was annealed to 
1µg of M13mp18 DNA (New England BioLabs). The primer was then elongated using 
Klenow polymerase (New England BioLabs) in a 50µL reaction containing 0.1mM 
dCTP, dGTP, and [α-32P] dATP. After 20 min of incubation at room temperature, 0.1mM 
dATP was added and the reaction incubated for another 20 min. Then, 0.5µL of labeled 
substrate was used in each reaction. LT purified on IgG Sepharose was incubated with 
the substrate in helicase assay buffer (20mM Tris-HCl [pH 7.5], 10mM MgCl2, 1mM 
DTT, 0.1mg/mL BSA, and 5mM ATP) at 37°C for 30 min. The reaction was stopped by 
adding SDS to a final concentration of 0.2% and EDTA to 50mM. Total reaction 
mixtures were resolved by electrophoresis on 11% non-denaturing polyacrylamide gels. 
The gels were dried and subjected to autoradiography. 
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6.16: Calf-intestinal Alkaline Phosphatase (CIP) Assay  
 Forty-eight hours post transfection, cells were lysed in lysis buffer (50mM Tris-
HCl, pH 8.0, 150mM NaCl, 10% Glycerol, 1% NP-40, 5mM MgCl2, 1mM DTT, and 
protease inhibitors) and passed through a 26-gauge needle 5 times. Lysates were 
incubated on ice for 20 min with occasional vortexing.  Lysates were then spun down at 
5,000rpm for 5 min at 4˚C.  Cleared supernatants were collected. A Bradford assay was 
performed to determine protein concentration and lysates were then diluted to 1mg/ml 
with lysis buffer. A 100µg aliquot of lysate was used for CIP treatment: NEB buffer 3 
was added to the lysate to a final concentration of 1X Buffer, and the solution was 
incubated at 37˚C for 5 min. The samples were then treated with 50 units of CIP for 30 
min at 37˚C. Samples were boiled in sample buffer and immunoblotted. 
 
6.17: Annexin V Staining  
 C33A cells were transfected with pEGFPC1, pEGFPC1-MCPyV LT, or 
pEGFPC1-MCPyV LT S816A. 24 hours post transfection, cells were washed with 
binding buffer (10mM HEPES [pH 7.4], 140mM NaCl, 2.5mM CaCl2), stained with 
Annexin V-PE for 10 min, washed once more with binding buffer, and fixed with 3% 
paraformaldehyde for 20 min. Nuclei were counterstained with DAPI.  
 
6.18: Retrovirus Production and Stable Cell Line Construction  
 293T cells were cultured in 10 cm dishes to reach 95%-100% confluency. 
pLPCX-based plasmids (pLPCX-Cherry-LacI, pLPCX-MCPyV LT 1-817, and pLPCX-
MCPyV LT 1-817 S816A), pVSVG, and pMD-gagpol were co-transfected into 293T 
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using Lipofectamine 2000 transfection reagent. After 48 hours, the packaged retroviruses 
in the supernatant were harvested and filtered through a 0.45µm filter before transducing 
C33A and HeLa cells. At 48 hours post-infection, the transduced cells were selected 
using 0.625 µg/ml or 1 µg/ml puromycin, respectively, for 4 days. Expression of MCPyV 
LT was confirmed by immunofluorescent staining and western blotting, and the selected 
cells were maintained as stable cell lines in DMEM supplemented with puromycin. 
  
6.19: In Vitro phosphorylation Assay  
 To activate ATM and ATR, U2OS cells were treated for 4 hr with 4µM etoposide, 
which induces double-strand DNA breaks. Treated cells were harvested and re-suspended 
in buffer A [10mM HEPES [pH 7.9,] 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM 
DTT, 0.2mM PMSF, 3mM sodium butyrate, 1mM NaF, and 100µM Na3VO4, 
supplemented with protease inhibitor cocktails (Roche) and S/T protein phosphatase 
inhibitor cocktails (Sigma)], and incubated on ice for 10 min.  NP-40 was added to a final 
concentration of 0.02% and cells were vortexed for 10 seconds. Nuclei were separated by 
centrifugation at 4,000rpm, 10 min, 4°C. Isolated nuclei were lysed in buffer B [20mM 
HEPES [pH 7.9], 0.5M NaCl, 1mM EDTA, 1mM EGTA, 1mM DTT, 0.2mM PMSF, 
3mM sodium butyrate, 1mM NaF, and 100µM Na3VO4, supplemented with protease 
inhibitor cocktails (Roche) and S/T protein phosphatase inhibitor cocktails (Sigma)] by 
passing through a 22-gauge needle 10 times, followed by rotation at 4°C for 1 hour. 
Nuclear extracts were isolated by centrifugation at 14,000rpm, 10 min, 4°C.  
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 Nuclear extracts (500µg) were mixed with 10µg rabbit anti-ATM, 10µg mouse 
anti-ATR, or 10µg normal rabbit IgG together with 10µg normal mouse IgG. Nuclear 
extracts and antibody mixture was rotated at 4°C for 2 hours, and then 10µl protein G 
agarose beads (Invitrogen) were added. Mixtures were rotated for another hour at 4°C. 
Proteins bound to the resin were washed four times with KCl buffer (20mM Tris [pH 
8.0], 10% Glycerol, 5mM MgCl2, 0.1% Tween-20, 150mM KCl, 0.1mM PMSF, 3mM 
sodium butyrate, 1mM NaF, and 100 µM Na3VO4, supplemented with protease inhibitor 
cocktails (Roche) and S/T protein phosphatase inhibitor cocktails (Sigma)). Resin was 
then equilibrated once with kinase buffer (20mM HEPES [pH 7.6], 50mM NaCl, 10mM 
MgCl2, 1mM DTT, 20mM MnCl2 and 1mM NaF). IIT-MCPyV LT was purified as 
previously described (14) and treated with CIP as described in Section 6.16. MCPyV LT 
was cleaved by AcTEV protease (Invitrogen) following the manufacturer’s instructions.  
 
 Equilibrated resin (10µL) with purified ATM or ATR proteins was mixed with 
30µl kinase buffer, 1µg purified MCPyV LT, 200µM ATP, and 0.5µl of 3,000Ci/mmol 
[γ-32P] ATP. Kinase assay was performed at room temperature or 37˚C for 30 min. 
Proteins were separated by SDS-PAGE, and the gel was subsequently dried at 80°C for 
30 min. Autoradiography was performed as previously described (50). 
  
6.20: Glutathione S-Transferase Pull-Down Assay  
 BL21(DE3)pLysS E. coli were transformed with pGEX-MCPyV LT or pGEX 
vector. Bacteria were lysed with lysis buffer (10mM Tris-HCl [pH 8.0], 50mM NaCl, 
0.4mg/ml lysozyme, 2mM DTT, 0.1mM EDTA, supplemented with protease inhibitors) 
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before running through Q-sepharose (Sigma) and SP-sepharose (Sigma) columns. The 
SP-sepharose column was washed with buffer (50mM Tris-HCl [pH 8.0], 150mM NaCl, 
2mM DTT, 0.1mM EDTA, supplemented with protease inhibitors) before elution with 
the same buffer containing  400mM NaCl. Elution was then incubated with GSH-agaorse 
(Sigma) at 4°C for 2 hr. GSH-agarose was washed five times with wash buffer (20mM 
Tris-HCl [pH 8.0], 5mM MgCl2, 0.1% Tween-20, 100mM KCl, supplemented with 
protease inhibitors). Bound proteins were used for GST pull-down assay. Briefly, U2OS 
nuclear extracts was prepared as previously described (156) and incubated with beads 
bound with GST or GST-LT at 4°C overnight. The beads were washed three times with 
0.5ml of 0.1 M KCl buffer and eluted with 30ul of SDS-PAGE sample buffer. 
  
6.21: Clonogenic Assay  
 C33A cells stably expressing Cherry-LacI, LT 1-817 or LT 1-817 S816A were 
plated in triplicate at 5 X 103 cells/well in a 6-well plate, and cultured in DMEM medium 
with 10% FBS and 0.625µg/ml puromycin for 10 days. The cells were then fixed with 
methanol and stained with 0.5% methylene blue. 
 
6.22: Luciferase Assay 
 293 cells were plated in triplicate at 2 X 103 cells/well in a 6-well plate and 
cultured in DMEM with 10% FBS.  Cells were co-transfected with the luciferase reporter 
plasmid and viral protein expression constructs indicated in the figure legends using the 
calcium phosphate method (50).  Cells were collected at the indicated time points using 
the Reporter Lysis system (Promega) following the manufacturer’s instructions.  Protein 
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concentration was measured by NanoDrop.  Luciferase activity was measured using the 
Luciferaase Assay System (Promega) according to the manufacturer’s instructions and 
normalized to protein concentration.  For ISRE activation in Figure 4.2, cells were 
stimulated 24 hrs post transfection with 1,000units/per well recombinant IFN-α, and 
collected 48 hrs post transfection.   
 
6.23: Statistical Analyses 
 Prism software was used to perform a one-way ANOVA test. A p < 0.05 was 
considered statistically significant. 
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